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Introduction 
Cardiovascular diseases (CVD) are serious public health problems with growing 
substantial concern. As the leading cause of death worldwide for both biological sexes, 
The Centers for Disease Control estimate that in the United States alone, 610,000 
Americans die from cardiovascular diseases each year1.  Unfortunately, due to the complex 
physiology of the circulatory system as well as the complicated pathogenesis involved in 
diseases of the heart2, a gold standard for effective primary and secondary prevention is 
uncertain. Needed are evidence-based prevention programs designed to optimize health 
and vascular wellness.    
Cardiovascular diseases are defined broadly as disorders pertaining to the heart 
and or blood vessels3. As an umbrella term for several complications, diseases of the heart 
vary in regards to symptomology and levels of potential irreversible damage3,4. Diseases 
of the blood vessels supplying the heart, brain, and appendages can lead to myocardial 
infarction, stroke, and oxygen deprived tissue death3,4. The complexity of the risk factors 
contributes to the development and pathogenesis of CVD, making direct causes elusive. 
Multiple risk factors act synergistically to cause the hallmark signs of CVD, including 
chronic inflammation and abnormal lipid metabolism2-4. Atherosclerosis, a precursor to 
many cardiovascular complications, is recognized as a chronic low-grade inflammatory 
disease of human arteries2,5 beginning within damaged vascular endothelium. In a 
systematic review published in 2016, Gimbrone et al6 referred to endothelial tissue as the 
“continuous cellular lining of the cardiovascular system”6. This tissue becomes damaged 
by various stressors including bacterial toxins, tobacco smoke, elevated blood glucose, 
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and poor diet. The vessel wall becomes vulnerable with increased permeability, allowing 
for low density lipoprotein (LDL) molecules to become trapped within the layers of the 
arterial wall6. This interaction triggers a complex pathogenic cascade into motion to signal 
the accumulation of macrophages, which modify the LDL particle into a premature fatty 
lesion or simply, a foam cell6-9. The endothelial cells become activated by this chemical 
cascade, increasing the expression of multiple chemicals secreted from damaged vessel 
cells and macrophages6-9. Continued structural maturing of fatty lesions result in the 
synthesis of a fibrous outer layer that protects a lipid dense, toxic core6. Gimbrone6 notes 
that within one individual, multiple atherosclerotic plaques may coexist within the circulatory 
system. With that, each lesion may progress at its own stage of evolution beginning with 
an initial phase of endothelial dysfunction6. Dysfunction localized within the endothelial 
cells may signal various developmental changes within the lesion(s) 6-9. Continuing this 
discussion of lesion progression, this introduction will outline the integration of inflammatory 
processes and lipid metabolism in the development of an atherosclerotic lesion, paying 
specific attention to various biomarkers of dysfunction. 
In a scientific statement written by health professionals from the Centers for Disease 
Control regarding inflammatory molecules and CVD10, authors note that all stages of 
development of an atherosclerotic lesion from initial injury to complication are pieces of 
inflammatory response to injury10. The established lesion signals the body’s primal 
response to tissue injury and contains multiple types of inflammatory cells that contribute 
to instability within the plaque6-10.  An increase in instability by pro-inflammatory cells may 
cause the plaque to dislodge itself from the arterial wall. A ruptured plaque may travel from 
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its location of origin and ultimately occlude arteries and block blood flow to various vital 
organs or appendages2-10. As a result, vital tissues stop receiving nutrients and oxygen 
thus contributing to various heart disease related events, including cerebral vascular 
accidents, peripherary artery disease, and myocardial infarction. Two specific inflammatory 
cell types involved in atherosclerosis, cellular adhesion molecules (CAMs) and pro-
inflammatory cytokines, are secreted from endothelial and inflammatory cells and 
contribute to lesion progression2,4-10. Due to their influence on various mechanisms of 
cellular function, CAMs may serve as important diagnostic markers of early endothelial 
injury7. Specific CAMs of interest include intracellular adhesion molecule (ICAM) and 
vascular cellular adhesion molecule (VCAM). In addition to CAMs, cytokines contribute to 
plaque instability2,4, overall inflammatory response2,4 and may serve as early biomarkers 
of cardiovascular risk as well as fully developed CVD2,4. Specific CVD-related cytokines of 
interest include C-reactive protein (CRP) and interleukin-6 (IL-6).  
 Cellular Adhesion Molecules. In 1997, Devaux, et al.11 published a tissue study that 
reported significant expression of cellular adhesion molecules in tissue samples from failing 
human hearts11. Furthermore, Devaux notes how cellular adhesion molecules interact with 
immune cells to allow for the migration of white blood cells to the site of inflammation11. 
Since 1997, several studies note the selective adhesive properties of CAMs for pre-
macrophage cells, as they are overlying the atherosclerotic plaque causing an increase in 
migration of immune cells to the site of vessel damage6-11. Components of oxidized LDL 
particles may act as triggers for CAM expression inducing the atherosclerotic inflammation 
process6-11 suggesting that persistent ICAM expression could be a characteristic of chronic 
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inflammatory disorders11. Soluble VCAM may be present in acute damage to the 
endothelium within major vessels11,12 and has been reported to be correlated with severity 
or “lesion burden” in atherosclerosis6-12.  
Inflammatory Cytokines. In 2004, Kanda et al13 published a systematic review 
focusing on inflammatory cytokines and their clinical significance for cardiac patient care. 
Researchers noted the importance of understanding cytokines for clinicians to determine 
the severity of atherosclerosis as well as the role cytokines play in viral infections of the 
heart muscle and cardiac tissue rejection after grafting or transplant13. Produced by 
damaged endothelial cells and the immune system13, the IL6 cytokine may be a potent 
activator of immune response as well as a potential stimulator of CRP and other acute 
phase proteins13. Clinicians reported elevated IL6 levels within the diseased cardiac 
muscle as well as in systemic circulation in the presence of heart failure while other 
inflammatory biomarkers were normal13. Increased levels of circulating IL6 have been 
associated with disease severity and therefore could serve as important biomarkers of 
heart disease related outcomes such as unstable angina and heart failure13. In addition, 
elevated levels of IL6 associated with less ability for the heart to pump blood, lower cardiac 
function, and poor prognosis13. IL6 may also be an important predictor of localized cardiac 
dysfunction and endothelial deterioration as it is secreted during several developmental 
events noted in the timeline of maturing plaques6,13. Due to the involvement in a localized 
inflammatory response, researchers speculate that this cytokine may be a crucial marker 
of multiple atherosclerotic lesions; with each lesion potentially progressing at independent 
rates, IL6 may be an important determinant of biological lesion stage6,13.  
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While researchers note that IL6 may serve as a better predictor of localized early 
endothelial dysfunction, inflammatory cytokine CRP may serve as a more accurate 
indicator of systemic wide inflammation in patients with cardiac complications2,6-9,11. 
Researchers note that these two cytokines may be connected since IL6 has been found to 
act as a potent stimulus of CRP production in the liver6,11.  In 2013, Stoner and colleagues 
investigated inflammatory biomarkers and their contribution to cardiovascular disease2. In 
a systematic review, Stoner et al2 corroborates other research studies by noting that CRP 
can be viewed as a predictor for future CVD events, including myocardial infarction2,6,11. 
Researchers also note that due to the complexities of CVD, certain cytokines and other 
inflammatory biomarkers may offer more insight to prognostic information while others may 
be more instrumental in predicting cardiovascular disease events2. It is evident that chronic 
inflammatory cytokines have some influence on various cardiovascular disease 
complications. A reduction in inflammatory mediated pathways may contribute to improved 
arterial function thus possibly contributing to a healthier heart and therefore, a reduction in 
mortality.  
Serum Lipid Disruption. Similar to the primal response of the inflammatory process, 
the presence of tissue injury or chronic inflammation has been reported to trigger the 
disruption in serum lipid levels as well as the inherent biochemical composition of lipid 
molecules14,15. In 2004, Esteve et al published an article examining the relationships with 
dyslipidemia, inflammation, and atherosclerosis. With activation of the inflammatory 
cascade, an increase in triglycerides14 is also noted. Inflammation may also affect enzyme 
activity of lipoprotein lipase, a vital player in lipoprotein metabolism14,16. Cytokines including 
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CRP and IL6 have been noted to be elevated with serum lipid disruption and to normalize 
with resolving TG levels14.  In addition, rising IL6 levels have been associated with 
decreasing HDL and reverse cholesterol transport. Interleukin 6 may trigger composition 
changes of lipoproteins by increasing ratios of cholesterol and TG rich substances14,15. The 
inflammatory process may also result in dysregulation of the LDL receptor resulting in 
accumulation of particles, which are prone to oxidation14,15. Oxidized LDL is more 
pathogenic and may serve as important precursors to foam cells, a premature 
atherosclerotic lesion14. Together these findings further reinforce the proposed integration 
of lipid metabolism within the inflammatory cascade. 
It is evident that the inflammatory response to endothelial injury acts synergistically 
with molecules of lipid metabolism thus contributing to cardiovascular disease related 
outcomes. Lifestyle approaches for both primary and secondary prevention of CVD as well 
as chronic inflammation and dyslipidemia that highlight healthy dietary intake have become 
the focus of many treatment modalities. Recently praised in the Scientific Report of 2015-
2020 Dietary Guidelines17, the Mediterranean diet is a dietary pattern with promising health 
benefits. In addition, Mediterranean areas have lower morbidity rates and increased 
longevity18. The Mediterranean Diet (MD) refers to the dietary pattern of its location. First 
introduced by Dr. Ancel Keys in the 1960s18, the MD combines a variety of minimally 
processed food groups in moderation to provide a balanced, satiating meal pattern18. The 
MD emphasizes the consumption of monounsaturated and polyunsaturated fats (primarily 
in the form of olives, olive oil, and nuts) as well as the daily consumption of vegetables, 
fruits, low fat dairy products, and whole grains18,19. In addition to these guidelines, 
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consumption of fish twice weekly, poultry, legumes, and tree nuts are recommended. Eggs 
may be consumed 7 days a week. Individuals following the MD are encouraged to reduce 
the servings of processed items and red meat to at least 1-2 times per week. Moderate 
consumption of alcohol (in the form of wine at 1 drink/day for women and 2 drinks/day for 
men) is allowed. Physical activity to promote health and overall well-being is encouraged.  
In addition, the nutritional guidelines note that these dietary factors specific to the 
Mediterranean diet are contributors to a reduction in metabolic disturbances commonly 
seen in individuals that consume a poor quality diet17. The report defines a suboptimal diet 
is as a dietary pattern with low fruit and vegetable intake, infrequent consumption of 
seafood, nuts, and legumes with increased consumption of sodium rich and processed 
foods17. These characteristics of poor diet quality are eliminated when one follows a 
Mediterranean diet. 
The Mediterranean diet and various health complications have been a focus of many 
types of research efforts including retrospective, prospective, and clinical trials. Among 
important literature, both the Lyon Heart Study (LHS)20 and the Prevención Con Dieta 
Mediterránea (PREDIMED)21 have been sources of promising evidence in relation to 
reducing and preventing CVD events.  These studies were the first to investigate the 
cardio-protective effect of the Mediterranean diet on cardiovascular disease events using 
a randomized and controlled setting. The LHS compared a traditional MD to a control diet 
while the PREDIMED trial investigated the effect of enhanced Mediterranean diets with 
olive oil and nuts versus a low fat diet only. The PREDIMED trial extended MD investigation 
by questioning key food components of the MD pyramid21. One of the first randomized 
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control trials with a longitudinal premise to investigate the cardio protective effect of the 
Mediterranean diet, the PREDIMED study spanned eleven primary care facilities across 
Spain and continues to deliver positive results. Cited in many research reports, these rather 
historical studies have outline beneficial effects of the MD for both cardiovascular disease 
and inflammation. Chiva-Branch et al5 cites PREDIMED results in a systematic review: 
greater adherence to MD is associated with a reduction in CVD events and related 
deaths5,21. After 5 years, a relative risk reduction of major CVD events (MI, stroke, death) 
by 30%5,21. In addition, Chiva-Branch notes that two sub-studies of the PREDIMED trial 
revealed that after a 3-month MD dietary intervention a reduction in serum expression of 
CRP was observed5. In another sub-study of PREDIMED, researchers were able to 
attribute these serum reductions to increased adherence to the MD as well as increased 
consumption of extra virgin olive oil, nuts, fruits, and vegetables5.  
Many research efforts in addition to the PREDIMED21 study have taken further steps 
to look closer at the specific roles of olive oil and tree nuts in the beneficial responses 
observed by individuals following the Mediterranean diet. As mentioned above, both olive 
oil and tree nuts are priniciple sources of dietary fat within the Mediterranean diet 
pattern18,19. In a report published by Rigacci et al75, the nutraceutical properties of olive oil 
in particular are discussed as well as their proposed benefits noted specifically for 
inflammatory atherosclerosis and CVD. Olive oil contains strong antioxidant properties that 
pose as a potent combator of localized and systemic inflammatory responses seen in 
atherosclerotic disease75. Specific polyphenols isolated in the olive plant have been noted 
to favor longevity while reducing the inherent inflammatory response75. In regards to tree 
  9	
nuts, Souza et al76 notes a nutrient profile containing high levels of bioactive substances 
that influences a reduction in oxidative stress causing a protective effect against 
cardiovascular alterations76. In addition to these findings, Souza et al76 discusses the 
importance of consuming a mixture of nuts to help intensify the cardio-protective and anti-
inflammatory benefits attributed to nuts76. Researchers describe a “balancing effect of 
nutrients” such as mono- and poly-unsaturated fats and minerals to targe specific disease 
related markers involved in atherosclerotic cardiovascular disease76. Due to the growing 
body of evidence pertaining to the Mediterranean diet pattern and its principal sources of 
dietary lipid (olive oil and nuts specifically), it is important to consider these key components 
of the MD as they do not diminish the overall dietary quality. 
Taken together, these positive findings in regards to the MD dietary pattern, its key 
sources of lipid, and CVD support the beneficial effect of a Mediterranean diet pattern. 
However, it still remains unclear which particular characteristics of the MD interventions 
influence the greatest beneficial effect on cardiovascular disease events, inflammatory 
biomarkers, and serum lipid measures. It is also important to note that many of the current 
reports on MD and CVD yield controversial results and make it difficult for researchers to 
observe the efficacy of a dietary pattern over time and across multiple populations. These 
findings suggest further investigation is warranted to understand the connection between 
the Mediterranean diet patterns, cardiovascular disease events, and inflammatory 
cytokines.  
Purpose and Specific Aims 
 The purpose of this work is to study the relationship of the MD and cardiac related 
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events as well as potential diagnostic markers of disease severity by conducting a high 
quality meta-analysis. Due to the nature of the extracted data, two researchers and a third 
party expert (TBHM) recommended two different Meta analytic approaches a univariate 
(using fixed and random-effects assumptions) and a multivariate (using random-effect 
assumptions) approach; both approaches will include mixed-effects assumptions when 
predictors are included in the models. In addition to CVD related events and inflammation, 
the majority of studies included serum lipid measures as outcomes. Due to the apparent 
integration of inflammation and lipid metabolism as well as the increasing burden of CVD 
related complications, the following outcome measures were chosen for evaluation under 
both random-effect assumptions: 1) total CVD related events, 2) myocardial infarction, 3) 
CVD related death, 4) c-reactive protein, 5) interleukin 6, 6) intracellular adhesion 
molecule, 7) vascular cellular adhesion molecule, 8) triglycerides, 9) low density 
lipoprotein, and 10) high density lipoprotein. Due to the nature of included data as there 
are multiple subgroups per study, researchers determined a multilevel meta-analytic model 
was implemented to account for dependencies within the dietary comparisons. Therefore, 
under multivariate assumptions the following outcome measures were chosen for further 
investigation: CRP, IL6, ICAM, VCAM, TG, LDL, and HDL.  
Several specific aims under each Meta analytic approach are outlined in detail below 
with the analysis performed.  
Univariate Meta-Analytic Aims. 
1. to obtain overall effect sizes under fixed- and random-effects assumptions for each 
outcome of interest (total CVD related events, MI, CVD death, CRP, IL6, ICAM, 
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VCAM, TG, LDL, and HDL) 
2. to evaluate the variability/consistency across current available literature pertaining 
to this topic 
3. to explain the variability across the study population using the moderator or predictor 
variable, intervention length 
Multivariate Meta-analytic Aims. 
1. to obtain overall random effect sizes for each outcome of interest (CRP, IL6, ICAM, 
VCAM, TG, LDL, and HDL) while accounting for multiple dietary comparision groups 
within each included study 
2. to evaluate the variability/consistency across current available literature pertaining 
to this topic by examining the differences between each dietary comparision group  
3. to further explain the variability across the study population using moderator or 
predictor variables coded during the data extraction process 
The primary hypothesis for this paper is that both random and multilevel effects for 
outcomes of interest (CVD related events, inflammatory biomarkers, and serum lipid 
markers) will favor the Mediterranean diet interventions compared to baseline with a null 
hypothesis that the MD will have no impact on CVD related outcomes of interest. The 
second hypothesis is that the efficacy of the MD interventions with differ across studies for 
each of the outcomes in question; some interventions will have significant effect while 
others will not, allowing researchers to indicate benefit of the MD interventions over the 
control group. Particularly under multilevel assumptions, the individual Mediterranean diet 
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comparison groups will significantly differ from one another and will allow researchers to 
begin to observe dietary dominance of effect. The final hypothesis of this paper is that 
moderator or predictor variables related to sample characteristics and dietary intervention 
design will help explain potential sources of heterogeneity in both univariate and multilevel 
models. 
Methods 
Literature Search. Research studies published up until July 17th, 2015 were 
considered for the study sample. A comprehensive literature search was conducted with 
the assistance of the University of Connecticut Health Sciences librarian (JL), using a 
Boolean search approach with appropriate key words and Medical Subject Headings 
(MeSH). Examples of these search terms include, “Mediterranean diet,” “Mediterranean 
style diet,” “cardiovascular disease,” “heart disease,” “myocardial infarction,” “heart attack”, 
“stroke,” and “atherosclerosis.” Seven databases were searched including: PubMed, 
CINAHL, EMBASE (via Scopus), Academic Search Premier, PsycINFO, Agricola, and CAB 
direct, suggesting a comprehensive search strategy. Language was not restricted in these 
searches and translators were used when applicable. Please refer to Appendix 1 to view 
the comprehensive search details for each database. In addition to computer-assisted 
programs and electronic data base searches, all studies from Schwingshackl et al22 were 
also screened for inclusion. Please refer to Appendix 2 to review the study screening form 
used throughout the inclusion process. A list of excluded studies with corresponding 
reasons for exclusion is available upon request.  
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Selection Criteria. Original research articles that presented pre- and post- design 
results regarding MD and CVD related events (specifically, CVD related deaths and or 
myocardial infarctions) and or MD and at least one inflammatory biomarker of interest 
(CRP, IL-6, ICAM, VCAM) were included for analysis. Lipid measures were not a direct 
inclusion criterion rather merely a secondary analysis as the majority of reports reported 
both measures of inflammation and dyslipidemia. Reports investigating the efficacy of a 
balanced Mediterranean diet and or an enhanced Mediterranean diet with additional 
servings of olive oil or nuts on desired outcomes of interest were included for this analysis. 
Studies that did not provide baseline and post intervention data for CVD related deaths, 
heart attacks, or inflammatory biomarkers of interest were excluded. In addition, studies 
that focused only on specific particular components of the MD (such as just seafood, wine 
only, just olive oil, or nuts only) were excluded from analysis. Reports that failed to report 
necessary information to calculate effect sizes were also excluded. Relevance of included 
studies was assessed based on topic, keywords, title, and abstract by two independent 
researchers (JS and MC) using a hierarchical approach. Researchers consulted an 
additional third party expert (TBHM) when needed to resolve disagreements regarding 
inclusion and exclusion criteria. The initial search yielded a total of 1,019 abstracts with 
relevant key words. After screening, hand searching, and organizing studies, 27 studies 
with a total of 229 comparisons were included for meta-analytic analysis. These studies 
met our inclusion criteria and focused on the efficacy of a Mediterranean diet on CVD 
related deaths, myocardial infarction, and inflammatory biomarkers. Refer to Figure 1 to 
view a Preferred Reporting Items for Systematic Reviews and Meta-analyses or PRISMA 
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flow diagram of inclusion and exclusion process. A list of excluded articles with reasoning 
is available upon request.  
Data extraction. A team of three Registered Dietitians, a physician, and a 
Biostatistician developed the comprehensive data extraction form and accompanying 
protocol originally in July 2014. The protocol included a manual and a data extraction form 
developed to guide our specific aims and hypotheses as well as to extract or code for 
information pertaining to sample characteristics including ethnicity, region and gender, 
intervention characteristics including length, diet type, macronutrient distribution, caloric 
intake, and participation in dietary counseling, as well as study design characteristics 
including experimental settings, control group, and number of interventions. The coding 
form and its manual included a total of 330 descriptive variables and other variables related 
to the general purpose of evaluating MD efficacy; both documents were initially pilot tested 
by two independent researchers in July 2014 (JS and MG) before a final review by 
additional experts (JB, JK, AK, TBHM). The data extraction form was later edited in August 
2015 for purposes of the new specific aims and hypotheses of this study and to ensure that 
researchers obtain necessary information from included studies. Each study was 
independently reviewed and coded by two independent researchers (JS and MC). 
Discrepancies were resolved between the two investigators privately or with the help of a 
third expert when necessary (TBHM). Refer to Appendix 3 to view the comprehensive 
coding form and corresponding data extraction manual.  
Risk of Bias. To assess risk of bias within included studies, the Cochrane 
Collaboration’s risk of bias tool was utilized23. With this tool, researchers score items with 
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either a minus sign (“-“) indicating high risk of bias; a plus sign (“+”) indicating moderate 
risk of bias; or a double plus sign (“++”) indicating low risk of bias for that parameter in 
question. Please refer to Figure 14 to review a graphical representation of Cochrane’s risk 
of bias tool. A total of 8 parameters were assessed addressing quality control issues 
relating to participant randomization procedures, subject allocation methods, blinding of 
subjects and personnel, attrition bias, and selective reporting. Methodological quality (MQ) 
rankings have been identified as an under- analyzed element of the data reported in meta-
analyses24-26. In this meta-analysis, MQ ratings calculated using a combined tool based on 
both Miller27 and Jadad’s28 methodological quality rating scales. Scores were coded 
individually and then totaled as separate variables for coding purposes. MQ was introduced 
as a possible moderator for multilevel analysis.  
Effect sizes. Individual effect sizes (ES) were calculated for each intervention with 
desired outcomes of interest to assess the magnitude of change observed for the 
Mediterranean dietary intervention. ES were calculated as the standardized mean 
difference, d 38. The standardized mean change is the difference between the pre-test and 
post-test means for the sample in question, divided by the pre-test or post-test standard 
deviation40. This allows for the comparison and or combination of results from several 
different study designs resulting in the elimination of the need to omit studies based on 
design differences. Individual effect sizes for each outcome were determined by calculating 
the standardized mean change for each study sample using data from various sources40. 
The data extracted for individual effect size analysis could be presented as means±s.d., t-
test, F- ANOVA, or mean±s.d. change, among other units and using the calculator the 
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different statistical information is transformed in a common metric, d, across comparison 
and studies. Individual effect sizes were calculated using an Excel calculator created by 
Huedo-Medina et al39. The effect size index, d+, follows a normal distribution from negative 
infinity to positive infinity, containing zero as the null value31. According to Cohen’s 
classification, the magnitude of the d value can be interpreted as 0.25 for small effect, 0.5 
for median effect, and 0.8 for large effect of outcomes of interest31.  
Statistical Analysis. All descriptive statistics about the study population were 
calculated using Excel29. Inter-Rater Reliability (IRR) was conducted for all categorical and 
continuous variables using IBM SPSS version 2230. Agreement of categorical variables 
were represented by the Kappa (κ) coefficient31and Pearson’s correlation coefficient32 was 
used to calculate continuous variable agreement. We tested for publication bias or 
asymmetries using two inferential tests, Begg33 and Egger’s34 as well as two graphical 
tests, the trim-and-fill method35 and funnel plots36. Remaining single level and multilevel 
statistical analyses with introduction of predictor variables was conducted using R version 
3.1.2 “Metafor” package37. All code for these analyses can be found in Appendices 4 and 
5. 
In addition to individual effect sizes, weighted fixed and random overall effect sizes 
were calculated at univariate and multivariate level41. The fixed effect model assumes that 
the data is coming from the same population thus only accounting for within study 
variance41. The random effect model assumes the data originates from multiple study 
populations thus accounting for both within and between study variance41. Mixed-effects 
models were run also using different predictors in the model. In addition to a univariate 
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meta-analytic approach, random- and mixed-effect models were developed for multivariate 
analysis by incorporating the inner and outer study variance covariance matrix, within the 
multilevel model. To test for heterogeneity, Cochran’s Q and I2 were calculated. Cochran’s 
Q tests for significance of heterogeneity42,43 while I2 represents the proportion of between-
study variability out of the total variablility44, presented in a numerical range from 0-100%. 
Following our hypotheses, moderator analysis utilizing mixed-effect models with maximum 
likelihood estimation of random-effect weights was performed using the variable length of 
intervention or number of weeks. To do so, the moving the constant technique44 was 
implemented to obtain estimates of the ES (d+) at various levels of the moderator variable. 
Corresponding confidence intervals (Cis) were obtained at different levels of interest. This 
technique was used to investigate the effect at minimum and maximum levels of the 
moderator variable weeks.  
A multivariate or mixed effect approach was then implemented due to the fact that 
many studies included in this paper contain multiple dietary interventions as well as primary 
and secondary endpoints. This type of hierarchy leads to a nested structure within the data 
set that needs to be accounted for42,45,46. These four interventions were categorized into: 
balanced Mediterranean diet (BMD), mixed nut enhanced Mediterranean diet (MDN), olive 
oil enhanced Mediterranean diet (MDOO), and control. The dietary interventions are 
clustered within reports resulting in significant dependencies related to the presence of 
multiple dietary interventions, which needs to be addressed. Ignoring dependencies within 
a data set can lead to bias within standard errors. This mistake would result in a Type 1 
error with an inflated α level45. To account for the nested structure and dependencies one 
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can explore more potential causes of heterogeneity by introducing explanatory or predictor 
variables to assess their influence on the magnitude of the effect size. In addition, 
correlations and associations between comparison groups may be observed and 
evaluated45. When interpreting multilevel results, the test for moderators or QM as along 
with its corresponding p.value should be noted. The QM is an inference test that helps 
determine model fit. A p.value of 0.05 or less indicates good model fitness.This value 
assists researchers in determining if the weighted effect sizes were significant and varied 
between each dietary comparison group. The individual p.values associated with each 
dietary comparison should correlate with the QM p.value and represent the significance of 
variability between dietary interventions within the multilevel model. 
 
Results 
Description of Included Studies. Inter-rater reliability testing resulted in a Kappa (k) 
coeefcient of 0.93 representing a 93% agreement between two independent coders for 
categorical variables. Pearson’s coefficient of r=1 was obtained for continuous variables. 
In total, there were 229 separate dietary interventions clustered within the 27 reports 
included for analysis. A description of included studies can be found in Table 1. Out of 27 
reports, only 19% of studies (5) measured cardiovascular disease related deaths and or 
myocardial infarction. In sum, the studies contained 20,937 participants with an average of 
mean age (SD) of 54(13.10) years. Participants involved in studies that measured CVD 
related events totaled 15,974 individuals and had existing CVD risk factors or cardiac 
complications. Subjects on average mostly male (30.2% or n=6324 were female). 
  19	
Individuals involved in studies that did not measure CVD events had either CVD risk 
factors, dyslipidemia, metabolic syndrome, diabetes mellitus, hypertension, obesity or a 
combination of these diseases. Table 1 describes disease type noted for each specific 
study. Depiction of baseline health status was provided in all 27 (100%) studies but only 
described the type of disease and or CVD risk factors as well as serum biomarkers at the 
beginning of intervention. Medications were not a part of any intervention however, 11 
(41%) studies reported continuance of drug regimens when deemed necessary on a per 
subject basis. In total, 16 (59.3%) interventions allowed current smokers in the studies. 
Over half of the included studies,18 reports in total (66.7%) did not specify weight loss as 
a result of interest; weight loss was not reported in these studies. A total of 20 studies 
(74.07%) were conducted in Europe, 3(11.11%) were conducted in the United States, 2 
(7.40%) in Australia, 1 (3.7%) in Africa, and 1 (3.7%) in Asia. All reports were published in 
English. The studies were published between 1994 and 2015 (mean = 2008, SD = 5.29). 
The average  impact factors is 10.93 (SD =14.25). Both one-on-one intervention and small 
group intervention levels were measured in 19 (70.3%) of the included studies. The 
minimum intervention length was 8 weeks and the maximum intervention length was 208 
weeks (mean=50.31, SD=58.58). No significant asymmetries were found using either 
statistical tests or the graphical techniques. A summary of the publication bias results can 
be found in Table 2.  
Univariate Approach 
 Random Effects. Please refer to Table 3 for an overall summary of univariate results 
with corresponding Q and I2 values. Overall the Mediterranean diet had beneficial effects 
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for 9 out of 10 outcomes of interest. Weighted effect sizes modeled under random effects 
assumptions attest that the MD had a significant overall effect on total cardiovascular 
related events (d+=-0.37, 95% CI -0.57 to -0.17), myocardial infarctions (d+=-0.32, 95% CI 
– 0.57 to -0.08), and CVD related death (d+=-0.44, 95% CI -0.78 to -0.089). The 
Mediterranean diet interventions exerted a favoring response on inflammatory biomarkers 
CRP (d+=-1.02, 95%CI -1.70 to -0.34) and IL6 (d+=-1.48, 95%CI -2.24to -0.73). Favorable 
results were also observed for cellular adhesion molecules, ICAM (d+=-4.32 95%CI -8.37 
to -0.26;) and VCAM (d+=-1.61, 95%CI -2.61 to -0.60). Results for lipid disruption indicate 
beneficial effect on serum lipid markers TG and LDL (d+=-0.63, 95%CI -0.95 to -0.31; d+=-
1.15, 95%CI – 1.70 to -0.60, respectively). Finally, results for HDL cholesterol (d+=0.15, 
95%CI -0.02 to 0.33) indicate an insignificant effect on this particular serum lipid biomarker. 
The ratio of the between-studies variability out of the total variability, I2, was noted to range 
from 91.21% to 99.97%, indicating that significant variability is present within the models. 
Please refer to Figures 2-11 to view forest plots for desired outcomes of interest pertaining 
to CVD related events, inflammation, and dyslipidemia. Significant heterogeneity or 
variability was found within the study population. 
Mixed-effect Meta-regressions. Meta-regressions using the moderator variable 
number of weeks or intervention length were conducted for each of the 7 outcomes of 
interest. A significant moderating effect by the variable weeks or intervention length, was 
noted for VCAM (β=-0.0607, 95% CI -0.1082 to -0.0148) The MD had a greater beneficial 
effect on serum VCAM levels in longer interventions,  In addition, researchers note that the 
longer subjects adhered to MD interventions, the greater the improvement in HDL 
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(β=0.0061, 95% CI 0.001 to 0.01). Intervention length accounted for 40.36% of 
heterogeneity between studies for the variable VCAM. In addition, the number of weeks 
explained 22.30% of heterogeneity within the study population in regards to MD on HDL. 
The moderator weeks accounted for some heterogeneity within the study population for 
both VCAM and HDL.  
Multivariate Approach 
A multilevel technique was used for analysis of both inflammatory biomarkers (k=89) 
and serum lipid measures (k=112). When applicable, four diet types were accounted for 
during analysis including a balanced Mediterranean diet (k=73) or BMD, enhanced 
Mediterranean Diet with mixed nuts (k=23) or MDN, enhanced Mediterranean diet with 
olive oil (k=24) or MDOO, and a control group (k=81). Results for BMD, MDN, and MDOO 
only will be discussed in this paper as the specific objectives aim to investigate 
Mediterranean diet groups only. The multivariate meta-analytic models were conducted for 
each outcome of interest using sub-groups of weighted effect sizes. Please refer to Tables 
5 and 6 for a summary of each multilevel model.  
C-reactive Protein. The multilevel model for CRP was conducted using 41 
comparisons clustered within 17 reports. Overall, the multilevel model revealed that a 
balanced Mediterranean diet (BMD) and an olive oil-enhanced Mediterranean diet (MDOO) 
exerted beneficial effects on CRP that were statistically different from the MDN group (d+=-
4.44, 95%CI –6.75 to –2.14; d+=-8.41, 95%CI -13.53 to -3.29 respectively). The mixed nut-
enhanced Mediterranean diet (MDN) was found to have an non-significant effect when 
compared to BMD, and MDOO groups (d+=-0.22, 95%CI –2.2 to 1.76). The multilevel 
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model for CRP revealed a test of moderator statistic or QM of 25.123 (p.value=<.0001), 
suggesting that the efficacy of dietary interventions differed significantly from one another 
with good model fit. Please refer to Table 5 to review the results of this multilevel model in 
table format. 
 Interleukin-6. The model for IL6 was conducted with 24 comparisons which 
were clustered within 10 reports. Overall, the multilevel model revealed that the BMD, 
MDN, and MDOO exerted beneficial effects that were statistically different from each 
dietary comparison according to the respective p.values (d+=-13.72, 95%CI –21.23 to –
6.23; d+=-3.74, 95%CI –6.10 to -1.38; d+=-2.97, 95%CI -4.78 to -1.15, respectively). The 
multilevel model for IL6 resulted in a QM value of 23.2952 (p.value=.0001), suggesting that 
the dietary interventions in question differed significantly from one another to some degree 
with good model fit. Please refer to Table 5 in the appendix to review the results of this 
multilevel mode in table format. 
Intracellular Adhesion Molecule. The multivariate model for ICAM was conducted 
with 13 comparisons clustered within 5 reports. Individual p.values at or above 0.05 confirm 
that the dietary comparisons did not differ in effect. Overall, the multilevel model revealed 
that BMD, MDN, and MDOO groups had a non-significant effect for ICAM serum levels 
under mixed-effect assumptions (d+=-2.86, 95%CI –6.03 to 0.31; d+=-2.05, 95%CI –17.56 
to 13.46; d+=-1.93, 95% CI -7.123 to 3.26, respectively). The inferential test for moderators 
or QM for this multilevel was 6.9250 (p.value=0.1399) suggesting the fit of this model was 
not significant. These values correlate with the results as the effect sizes for each dietary 
  23	
intervention did not result in statistically significant Cis with variability. Please refer to Table 
5 in the appendix to view the results for this multilevel model in table format. 
Vascular Cellular Adhesion Molecule. The multivariate meta-analytic model for 
VCAM was conducted with 11 comparisons that were clustered within 4 studies. Overall, 
the multilevel model revealed that MDOO was beneficial in regards to VCAM serum levels 
(d+=-3.31, 95%CI –6.48 to –0.14). Both BMD and MDN dietary interventions were both 
found to have an insignificant effect on VCAM that was not significantly different from the 
MDOO group (d+=-0.36, 95%CI –2.57 to 1.84; d+=-4.19, 95%CI –8.63 to 0.24, 
respectively). The multilevel model for VCAM resulted in a QM value of 39.8860 
(p.value=<.0001) suggesting good model fit and that at least one of the dietary 
comparison’s effect differed significantly from the others in question. Please refer to table 
5 in the appendix to view results for this multilevel model in table format. 
 Triglycerides. The multivariate model for TG was conducted with 40 comparisons 
that were clustered within 17 reports. Overall, the multilevel model revealed that beneficial 
effect on TG by BMD that was significantly different from MDN and MDOO groups (d+=-
3.0, 95%CI –4.91 to -1.08). The enhanced Mediterranean diets with mixed nuts was found 
to be insignificant under mixed-effect assumptions and did not differ significantly from one 
another (d+=-0.17, 95%CI –6.76 to 6.42; d+=-2.85, 95%CI –9.20 to 3.50 respectively). The 
inferential test QM revealed a value of 27.3081 (p.value=<.0001) suggesting good model 
fit as well as varying effect of dietary comparisons in question. Please refer to table 6 in 
the appendix to review the corresponding results for the TG model in table format. 
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 Low Density Lipoprotein. The model for LDL was conducted using a total of 34 
comparisons clustered within 14 studies. Overall, the multilevel model revealed that the 
BMD was beneficial for LDL levels and was significantly different when compared to MDN 
and MDOO groups  (d+=-3.46, 95%CI –5.53 to –1.38). Both of the enhanced Mediterranean 
diets were found to have insignificant effect on LDL markers (d+=-3.37, 95%CI –7.72 to 
0.98; d+=-3.5, 95%CI -8.34 to 1.32, respectively). The inferential test QM resulted in a value 
of 12.8939 (p.value=0.0118) suggesting decent model fit as well as a varying effect in 
regards to the dietary comparisons in question, specifically the BMD group. Please refer to 
table 6 to view the results of this multilevel model in table form.  
 High Density Lipoprotein. The model for HDL involved 38 comparisons clustered 
within 16 reports. Overall, the multilevel model revealed that BMD had a significantly 
different beneficial effect for HDL serum levels when compared to MDN and MDOO groups 
(d+=3.03, 95%CI 1.38 to 4.67). Both enhanced MD groups, MDN and MDOO, revealed 
insignificant results that did not vary from one another (d+=3.11, 95%CI -0.20 to 6.43; d+=-
1.58, 95%CI -4.73 to 1.57, respectively).  The inferential test or QM resulted in a value of 
18.8379 (p.value=0.0008) suggesting good model fit as well as a varying effect of the 
dietary interventions in question, specifically the BMD group. Please refer to table 6 in the 
appendix to view the results for the multilevel HDL model in table format. 
 
Moderator Analysis Using Multivariate Approach 
Please refer to Table 7 for complete description of moderator results, including point 
estimates, 95% confidence intervals, p.values, and corresponding I2 values for each dietary 
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comparison. I2 results ranged from 89.28% to 99.95% within all multilevel models using 
moderators. Studies included in this analysis varied in terms of intervention length, mean 
age, number of female participants, region of study conduction, funding source, participant 
recruitment locations, level of intervention, and methodological quality. Please refer to 
Table 9 for a complete list of moderators that produced non-significant results. Refer to 
Table 10 for a complete list of moderator variables that were unable to be analyzed due to 
lack of reporting. Additional significant trending associations for each moderator of interest 
can be observed for all CVD related outcomes. Please refer to Tables 8 through 14 to 
review important statistics for observed beneficial associations. The effect of the moderator 
is presented as mods and is considered an unstandardized beta (β). This value represents 
the quantity of how the effect size behaves, whether it is increasing or decreasing based 
on each unit of the moderator variable in question. Individual effect sizes under multivariate 
assumptions are listed for each diet with the corresponding confidence intervals 
representing the efficacy of the reference dietary intervention when compared to other 
dietary comparisons and adjusted for number of weeks. The corresponding p.value 
represents the significance in variability between the dietary comparison factors.  
In regards to design characteristics, intervention length was found to have an overall 
moderating for the VCAM model, β=-0.06 (95% CI -0.09 to -0.03) only. In general, BMD 
group had greater beneficial effects on biomarkers CRP, IL6, and TG in longer 
interventions when compared to MDN, MDOO, and control groups. Both enhanced 
Mediterranean diet groups, MDN and MDOO, had an enhanced significant effect on LDL 
when adjusted for intervention length and compared to BMD and control diets. The longer 
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the intervention length, the MDN group exerted a greater effect on IL6 in longer 
interventions while the MDOO group was beneficial for CRP. In addition to number of 
weeks, region of study conduction was tested for its moderating effect. Studies conducted 
in Europe measuring LDL had moderating effect β=-2.0057 (95% CI -3.1102 to -0.9013). 
Results show that when adjusted for study region, BMD exerted a greater beneficial effect 
on CRP and TG that differed significantly from the enhanced Mediterranean diet groups. 
The MDN comparison groups had a statistically different effect on CRP and ICAM when 
compared to BMD and MDOO groups while MDOO groups were more beneficial for CRP 
when controlled for study region. In regards to VCAM (k=11), all studies were conducted 
in Europe thus resulting in output error during analysis. Researchers eliminated the piece 
of code pertaining to factored moderators in order to obtain observable results. Both BMD 
and MDN had beneficial effects on VCAM when adjusted for study region. Studies 
recruiting patients from a clinical setting acted as an overall moderating in the  IL6 model, 
β=-3.68 (95% CI -6.99 to -0.37) only.  Effect size of BMD on LDL after adjustment of 
recruitment location was more beneficial when compared to enhanced Mediterranean diet 
groups. The efficacy of the MDOO groups on LDL and CRP were influenced by subject 
recruitment and produced statistically different effects when compared to other 
Mediterranean diet groups.  In regards to ICAM (k=13) and VCAM (k=11), all subjects were 
recruited from a clinical setting resulting in errors in analysis output when using the factored 
moderator code. Beneficial effects were observed for BMD groups on VCAM and for MDN 
groups on ICAM and VCAM once the factored moderator code was eliminated. Funding 
source was also tested as a factored moderator for all inflammatory and lipid markers. 
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Sources of funding varied between each included study with a categorical classification of 
government source, academic source, private source, or multiple sources. Academic 
sources of funding had a modulating effect on VCAM, β=-3.57 (95% CI -4.67 to -0.47) as 
well as LDL, β=-2.08 (95% CI -3.87 to -0.30). In addition to academic funding sources, a 
modulating effect was also noted for private funding sources for TG, β=-0.61 (95% CI -1.19 
to -0.03) and LDL, β=-1.28 (95% CI -2.55 to -0.001). Finally, funding from multiple sources 
was found to have a modulating effect on TG, β=-0.87 (95% CI -1.50 to -0.23). 
Studies within the included population varied in regards to the level of intervention 
or supervision provided for subjects participating in the dietary interventions. Responses 
included one on one, small group interventions, supervised sessions, unsupervised 
sessions, or incentives. As previously stated in the descriptive results, the majority of 
studies conducted dietary interventions with small group processes. Due to the categorical 
nature of this variable, factored moderator analysis was conducted using the same syntax 
stated above. Under random-effect assumptions, small group intervention level had an 
overall moderating effect on the inflammatory biomarker, VCAM (β=-2.56, 95%CI -4.71 to 
-0.42).  In regards to the most common intervention level used in the interventions included 
for VCAM specifically, 82% of dietary interventions were conducted in small groups. The 
efficacy of the BMD groups on TG and LDL were influenced by small group intervention 
studies following adjustment. A beneficial effect was also noted for MDN groups on LDL. 
More intimate group sessions also enhanced the effect of the MDOO interventions on both 
CRP and LDL. 
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Within the included study population, researchers noted variance between reports 
based on randomized control trial methodological quality (MQ). In this meta-analysis, 
researchers used two measures of methodological quality or risk of bias, previously 
described in the methods section of this paper23,27,28. The total score calculated using the 
scale adapted by a third party expert (TBHM) from Miller27 and Jadad28 assessment tools, 
was introduced as a predictor or moderator variable for each variable in question. 
Methodological quality was found to not have an overall moderating effect on any of the 
inflammatory or lipid measures. Overall study MQ was found to have influence on the 
MDOO groups’ effect on CRP, IL6, and LDL studies after adjustment and comparison to 
other interventions.  In addition, the effect of MDN groups of IL6 and LDL were also affected 
by overall study MQ after adjustment. The magnitude of effect in regards to the BMD group 
on IL6 was also found to be affected by study quality.  
In regards to population characteristics, multilevel analysis reports that age did not 
have an overall moderating effect for any of the outcomes of interest. The effect of the 
balanced Mediterranean diet (BMD) on VCAM was found to have a greater beneficial after 
adjustment of subject age when compared to other Mediterranean diet groups. The 
beneficial effect of olive oil-enhanced Mediterranean diet (MDOO) groups was also 
enhanced by mean age for both CRP and VCAM. The mixed nut-enhanced Mediterranean 
diet groups (MDN) had statistically different effect on VCAM in older populations when 
compared to BMD and MDOO groups. In regards to number of female participants, BMD 
efficacy was significantly different than enhanced groups and influenced by number 
females reported in the dietary interventions in five out of seven factors. Serum markers 
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for CRP, IL6, VCAM, TG and LDL had significant effect sizes after adjusting for the number 
of females. Multilevel analysis reports a greater beneficial effect in female subjects 
allocated to MDN groups on the following outcomes IL6, ICAM, VCAM, LDL, and HDL. The 
MDOO group was more beneficial in female participants for CRP, VCAM, LDL, and HDL. 
Risk of bias was low for random sequence generation, allocation, blinding, 
incomplete outcome data, selective reporting, and other potential sources of bias for the 
many of studies. Low incidence of high risk of bias of included studies. Please refer to 
Figure 14 for a complete Risk of Bias Summary.  
Discussion 
The results of this high-quality meta analysis begin to shed light on the benefits of 
consuming a balanced Mediterranean diet as well as additional dietary enhancement with 
increased ratios of olive oil or mixed nuts on cardiovascular disease and associated 
markers of disease severity. The significant heterogeneity observed in this work was 
partially explained by intervention length, recruitment location, funding source, region of 
study conduction, and intervention level. In addition, by accounting for each comparison, 
researchers were able to further explore interesting associations between a balanced 
Mediterranean diet and two vital components needed to achieve the most balanced form, 
olive oil and nuts. To our knowledge, this is the first multilevel meta-analysis examining the 
efficiacy of different variations of the Mediterranean diet on CVD, inflammatory biomarkers, 
and serum lipid measures.  
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  Our findings that a balanced Mediterranean diet pattern as well as enhanced MDs 
with increased ratio of olive oil and mixed nuts is beneficial in reducing CVD related events 
and markers of disease severity compliment if not extend previous research efforts. 
Previously published meta-analyses published on the MD and CVD risk factors report 
similar beneficial effects on inflammatory biomarkers and serum lipid measures22,73,74In 
addition, these studies note similar associations in regards to moderator analysis using 
intervention length73,74, region of study conduction73,74, and intervention level25. In general, 
individuals adhering to a Mediterranean diet saw greater beneficial effects when studies 
were conducted in the Mediterranean basin and with longer duration. In the present meta-
analysis, as the majority of studies were conducted in Europe, specifically countries located 
in the Mediterranean basin, these findings illuminate the possible predictors of 
Mediterranean diet food quality, food culture, and overall access to traditional food 
components. Researchers also have considered the baseline health parameters for 
individuals in the Mediterranean basin. Further investigation is warranted to explore 
specific cultural food practices and their impact on cardiovascular health. In addition, 
participants who followed a balanced Mediterranean diet for longer interventions, saw 
greater reductions in CRP, IL6, and TG. Longer enhanced MD groups had greater effect 
on LDL for both mixed nuts and olive oil. Longer adherence to healthy dietary patterns may 
prove to be more beneficial for long term health and maintenance periods. Interestingly, 
our findings pertaining to intervention level or delivery of educational sessions to promote 
adequate compliance to dietary therapies, further extend the results of a recent meta-
analysis developed by our research team25. While the majority of studies were conducted 
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using small group proceedings, these findings further extend the existing literature on the 
importance of more targeted, personal interventions. Small groups may also bring in an 
additional peer support aspect, as study participants in the same group may be able to 
provide continued motivation from a more relatable source rather than a principal 
investigator. 
 To our knowledge, there is one meta-analysis specifically focusing on a 
Mediterraean diet pattern, endothelial function, and inflammation22. This 2014 meta-
analysis by Schwingshackl et al22 included 17 randomized control trials totaling 2300 
subjects. Overall, researchers noted a significant decrease in markers of endothelial 
dysfunction as well as reductions in specific inflammatory cytokines, CRP and IL6, and 
intracellular adhesion molecules. Our current findings compliment Schwingshackl et al22 in 
that significant reductions were also noted for CRP, IL6, and VCAM specifically.  
 One notable difference between Schwingshackl et al22 and this present meta-
analysis, is that we considered not only a balanced Mediterranean diet pattern but, 
additional MD interventions with increased ratios of olive oil and mixed nuts. One 
interesting recurrent theme worth noting throughout our multilevel results was the 
effectiveness of the enhanced Mediterranean diet with mixed nuts on interleukin-6 as well 
as the enhanced Mediterranean diet with olive oil on C-reactive protein. Perhaps these 
results begin to describe some of the targeted benefits observed for this specific dietary 
pattern. Thus, the question of interest is if health care professionals could provide a more 
targeted dietary therapy for these specific inflammatory biomarkers. This association 
reoccurring theme warrants further investigation into specific nutrient profiles and overall 
  32	
biochemical composition of these two Mediterranean diet staples. These results may 
further suggest an underlying biochemical mechanism and or connection between mixed 
nuts and interleukin 6 as well as for olive oil and c-reactive protein. Clinicians may 
eventually be able to choose to tailor dietary prescriptions depending on a patient’s specific 
clinical presentation. 
In summary, our research findings suggest a significant cardio-protective effect 
exerted by the Mediterranean diet that extends beyond a more general view of the dietary 
pattern. By implementing a multilevel meta-analytic approach, researchers were able to 
further explore more targeted strategies related to possible clinical predictors. By 
implementing a multilevel model, notable associations were observed that may provide 
insight in development of targeted dietary prescriptions for specific inflammatory 
biomarkers and serum lipid measures. Early detection of rising cellular adhesion molecules 
may provide insight to the beginning stages of the inflammatory response allowing for more 
rapid preventative care. In patients with existing complications, targeted dietary therapies 
using a greater proportion of olive oil may be suitable for patients with chronic systemic 
inflammation while an increased ratio of mixed nuts, may be more suitable for a localized 
reaction within the endothelium. 
Practical Application. The results of this multilevel meta-analysis contribute to the 
expanding wealth of evidence related to the Mediterranean diet and health, particularly 
cardiovascular related disease, inflammation, and serum lipid disruption. By attempting 
moderator analysis with only few variables with an overall effect, this meta-analysis 
demonstrates the importance of thoroughly reporting design characteristics, 
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randomization procedures, dietary intervention guidelines, behavioral interventions used, 
and tools used for compliance. Having more detailed information for extraction would 
allow for additional moderator analysis with hopes of continued identification of potential 
predictors that may influence effect size magnitude. This meta-analysis may be influential 
in various health care fields (medical, nutrition, and dietetics) as the level of intervention 
had significant influence and associations on many outcomes in question. These findings 
suggest that small group interventions may prove to be more beneficial and more 
motivating in regards to health behavior changes. Most studies that involved dietary 
education, enlisted the help of a Registered Dietitian to carry out dietary comparison 
instruction. Dietitians should have a primary role in dietary intervention trials as they are 
considered experts in the field of nutrition and dietetics. In addition, RDs are trained in 
various counseling techniques and strategies that may be implemented when dietary 
adherence is poor. These findings extend recent research results concerning 
Mediterranean diet education delivered in small group interventions. Garcia, et al25 notes 
in another high quality meta-analysis, that significant beneficial effects were found in 
studies that focused on small group education and intervention proceedings.  
Study Limitations and Strengths.  This meta-analysis has several limitations and 
strengths. One limitation would be that the significant heterogeneity between the studies 
still remains unexplained after both univariate and multilevel analysis. In addition, multiple 
coded variables did not have enough data reported to utilize in moderator testing. Due to 
inconsistent reporting, we were unable to control for macronutrient distribution, caloric 
content, or physical activity level within the models. There is also the potential for 
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ecological fallacy considering we did not have access to raw study data for this analysis. 
In that, we should be cautious about translating effect size into individual results. One 
final note of caution would be the nature of the data, for ICAM and VCAM specifically. 
Clinical measures for these markers had larger ranges of serum levels reported, which 
should be considered when interpreting results.  
There are multiple strengths for this meta-analysis. In regards to the search 
strategy implemented, our research team used a comprehensive literature search within 
seven electronic databases. A comprehensive coding form and manual was revised 
specifically for this paper and used for data extraction that resulted in 93% agreement 
between two independent researchers. Lastly, we performed a meta-analysis at two 
levels: univariate and multivariate. To our knowledge, this is the first meta-analysis to 
account for dependencies within the dataset to further explore dietary dominance and 
significant associations with population characteristics across the current literature on this 
topic.  
Future Research Directions. To our knowledge, this meta-analysis is the first to 
implement a multilevel technique to further investigate dietary dominance within the 
included sample. Researchers were able to observe some significant associations in 
regards to a balanced Mediterranean diet and enhanced Mediterranean diets with greater 
proportions of nuts or olive oil. In this analysis, mean differences are correlated due to the 
repeated use of sample information from the control group46. In order to further investigate 
dietary dominance, researchers have determined that the next logical step in this ongoing 
meta-analytic project would be a network meta-analysis47. Only conducted in few reports 
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and criticized for complexity, a network meta-analysis (NMA) allows for synthesis of both 
direct and indirect evidence observed within a network of trials with three or more 
comparison groups47. A NMA allows researchers to simultaneously compare multiple 
treatment groups within a single statistical model47. We feel that a NMA would be a vital 
statistical model to include within the developing wealth of research pertaining to the 
Mediterranean diet considering many studies are conducted with multiple dietary 
interventions. By using a network meta-analytic model, researchers would be able to rank 
treatment options from most beneficial to least beneficial thus providing more targeted 
results per outcome of interest.  
Conclusion 
The results of the present meta-analysis suggest that adherence to the overall 
Mediterranean diet as well as enhanced MD varieties, can have significant beneficial 
effects on cardiovascular disease related events, inflammatory biomarkers, and 
dyslipidemia. More high- quality intervention studies are needed to evaluate the 
relationship between the traditional MD and the specific roles of olive oil and mixed nut 
varieties play within this promising dietary pattern, food culture, and lifestyle. This high 
quality meta-analysis on the effect of the TMD and enhanced varieties on CVD related 
events, inflammatory biomarkers, and dyslipidemia markers contributes to the expanding 
wealth of research in favor of the Mediterranean dietary pattern effects on cardiovascular 
disease related outcomes.  
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Figure 1. PRISMA Figure Outlining the Process of Study Identification, Screening, 
Eligibility, and Inclusion 
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Note. N, number of participants; recruit, population recruitment; MHC, mild hypercholesteremia; NR, not reported; MD, Mediterranean 
diet; LFD, low fat diet; s.lipids, serum lipids; inflam, inflammation; BP, blood pressure; Ob, obesity; WT, weight; endoD, endothelial 
dysfunction; OWT, overweight; PREDIMED, Prevención con Dieta Mediterránea; DM, diabetes mellitus; CVDRF, cardiovascular 
disease risk factors; MDN, Mediterranean diet enhanced with mixed nuts; MDOO, Mediterranean diet enhanced with olive oil; WC, 
waist circumference; Ngenom, nutrigenomic; MD, medical doctor; CHD, coronary heart disease; events, CVD related events; comm, 
community; MetS, metabolic syndrome; vas, vascular; T2DM, type 2 diabetes mellitus; WD, Western Diet; CRF, chronic renal failure; 
CAD, coronary artery disease; OA, osteoarthritis; NI; no intervention; MDI, Mediterranean diet intervention; MDHI, Mediterranean diet 
high intervention; MDLI, Mediterranean diet low intervention; NMD, non Mediterranean diet; MyP, My Pyramid dietary guidelines for 
pregnancy and breastfeeding. 
 
Note on Dietary Assessment column:  
● Individual: A dietitian performed a dietary assessment, providing individualized needs for caloric intake and recommendations, 
for each participant. 
● Group: The study provided general dietary recommendations for the participants, such as a range of servings of certain food 
groups, calories based on gender, as opposed to tailoring diets to individual needs based on weight and height. 
● Supervised: Participants consumed foods in a supervised setting, where the researchers had control over participant food 
choices and quantity of food served. 
● Unsupervised: Participants food consumption was unsupervised by researchers, such as eating at home 
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Table 2. Publication Bias 
 
Outcome Egger's Begg's  
Total CVD Events p=0.0005 p=0.0031 
CRP p=0.0003 p=0.0031 
IL6 p=0.0003 p=0.0031 
ICAM p=0.0004 p=0.0031 
VCAM p=0.0706 p=0.6122 
TG p=0.4278 p=0.0002 
LDL p=0.1410 p=0.0026 
HDL p=0.6078 p=0.0812 
 
Note:  CVD, cardiovascular disease; CRP, c-reactive protein; IL6, interleukin-6; 
 ICAM, intracellular adhesion molecule; VCAM, vascular cellular adhesion 
 molecule; TG, triglycerides; LDL, low density lipoprotein; HDL, high density 
 lipoprotein. 
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Table 3. Summary of Univariate Results, Overall Effect Sizes, Homogeneity 
 
Outcome k d+ (95% CI) Homogeneity of d’s 
Random-Effects Q I2 p-value 
Total 
Events 
11 -0.3740 
(-0.5726 to -0.1753)* 
207.0914 98.63 <0.0001 
MI 6 -0.3236 
(-0.5681 to -0.0791)* 
67.7760 97.26 <0.0001 
CVD Death 5 -0.4365 
(-0.7838 to -0.0891)* 
139.3040 99.04 <0.0001 
CRP 26 -1.0174 
(-1.6963 to -0.3385)* 
478.1697 99.45 <0.0001 
IL6 17 -1.4823 
(-2.2389 to -0.7256)* 
607.8397 99.55 <0.0001 
ICAM 10 -4.3157 
(-8.3708 to -0.2606)* 
1330.1552 99.97 <0.0001 
VCAM 9 -1.6076 
(-2.6176 to -0.5976)* 
321.7464 99.69 <0.0001 
TG 24 -0.6306 
(-0.9481 to -0.3130)* 
513.2172 97.38 <0.0001 
LDL 23 -1.1505 
(-1.7021 to -0.5990)* 
625.2637 99.15 <0.0001 
Note: MI, myocardial infarction; CVD, cardiovascular disease; CRP, c-reactive protein; 
IL6, interleukin-6; ICAM, intracellular adhesion molecule; VCAM, vascular cellular 
adhesion molecule; TG, triglycerides; LDL, low density lipoprotein; HDL, high 
density lipoprotein; * indicates significant effect; Q represents Cochran’s Q 
indicating significance of heterogeneity; I2 represents the magnitude of 
heterogeneity; p-value represents the significance of heterogeneity. 
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HDL 24 0.1573 
(-0.00168 to 0.3314) 
178.1119 91.21 <0.0001 
 
 
 
Table 4. Moving The Constant Technique 
 
Outcome k Weeks d+ 
(95%CI) 
R2 p-value 
VCAM 9 12 -1.0507 
(-1.9091, -
0.1922)* 
44.32% <0.0001 
 9 52 -3.5121 
(-5.1715, -
1.8526)* 
HDL 23 8 -1.2384 
(-3.3518, 
0.8750) 
0.00% <0.0001 
 23 104 0.8898 
(-0.0879, 
1.8676) 
 
 
Note: VCAM, vascular cellular adhesion molecule; k, number of comparisons included 
in analysis; d+, effect size; * represents significant effect; R2 indicates the amount of 
heterogeneity accounted for; p.value represents significance. 
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Table 5. Summary of Multilevel Results, Overall Effect Sizes, and QM--Inflammation 
 
Biomarker k BMD MDN MDOO QM p. value 
CRP 41 -4.449  
(-6.7468 
to -
2.1430)* 
-0.2196  
(-2.2006 
to 
1.7615) 
-8.4106  
(-
13.5294 
to -
3.2918)* 
25.1234 <.0001 
IL6 24 -
13.7177 
(-
21.2286 
to-
6.2067)* 
-3.7366  
(-6.0974 
to -
1.3758)* 
-2.9667  
(-4.7842 
to -
1.1493)* 
23.2952 .0001 
ICAM 13 -2.8586  
(-6.0310 
to 
0.3139) 
-2.0525  
(-
17.5600 
to 
13.4551) 
-1.9325 
(-7.1266 
to 
3.2617) 
6.9250 0.1399 
VCAM 11 -0.3641  
(-2.5684 
to 
1.8402) 
-4.1933  
(-8.6259 
to 
0.2392) 
-3.3115 
(-6.4809 
to -
0.1420)* 
39.8868 <.0001 
 
 
Note: CRP, c-reactive protein; IL6, interleukin-6; ICAM, intracellular adhesion molecule; 
VCAM; vascular cellular adhesion molecule; *indicates significant results; QM represents 
test of moderators; p.value represents significance. 
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Table 6. Summary of Multilevel Results, Overall Effect Sizes, and QM-- Lipids 
 
Serum 
Lipid 
k BMD MDN MDOO QM p.value 
TG 40 -2.9992  
(-4.9145 
to-
1.0839)* 
-0.1682  
(-6.7587 
to 
6.4222) 
-2.8504 
(-9.1992 
to 
3.4985) 
27.3081 <.0001 
LDL 34 -3.4582 
 (-
5.5324 
to-
1.3841)* 
-3.3664  
(-7.7156 
to 
0.9829) 
-3.5086  
(-8.3435 
to 
1.3263) 
12.8939 0.0118 
HDL 38 3.0282 
(1.3819 
to 
4.6746)* 
3.1113 
(-0.2079 
to 
6.4304) 
-1.5818 
(-4.7361 
to 
1.5724) 
18.8379 0.0008 
 
 
Note: TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 
*indicates significant results; QM represents test of moderators; p.value represents 
significance of results. 
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Table 7. Significant Moderating Effect Under Mixed-Effect Assumptions 
 
Outcome Moderator ! 95% CI P.value 
IL6 recruitment -3.6840 (-6.9906 to -
0.3774)* 
0.0290 
VCAM weeks -0.0622 (-0.0948 to -
0.0297)* 
0.0002 
VCAM Intervention lvl -2.5683 (-4.7138 to -
0.4229)* 
0.0190 
VCAM fund (aca) -2.5682 (-4.6663 to -
0.4700)* 
0.0164 
TG fund (private) -0.6100 (-1.1929 to -
0.0290)* 
0.0403 
TG fund (multiple) -0.8664 (-1.5043 to -
0.2286)* 
0.0078 
LDL region -2.0057 (-3.1102 to -
0.9013)* 
0.0004 
LDL fund (aca) -2.0848 (-3.8684 to -
0.3011)* 
0.0220 
LDL fund (private) -1.2758 (-2.5503 to -
0.0012)* 
0.0498 
 
 
Note: IL6, interleukin-6; VCAM, vascular cellular adhesion molecule; lvl, intervention; 
LDL, low-density lipoprotein; fund, funding source; aca, academic; !, unstandardized 
beta; *indicates significant results; QM represents test of moderators; p.value represents 
significance of results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  59	
Table 8. Non-Significant Moderators 
 
Non-Significant Moderators 
Number and proportion of females 
Methodological Quality 
Number of interventions 
Ethnicity estimation 
Proportion of participants with any type of disease 
Number of participants with any type of disease 
Proportion of Participants taking any type of medication 
Number of participants taking any type of medication 
Type of medication use 
Experimental setting 
Length of counseling sessions 
Number of counseling sessions 
Publication year 
Language of publication 
Proportion of carbohydrate intake (<50% of ≥50%) 
Proportion of saturated fat intake (<10% or ≥10%) 
Proportion of total fat intake (<30% or ≥30%) 
Proportion of protein intake (<15% or ≥15%) 
Mean age of sample 
Assessment of dietary compliance 
Participation in dietary counseling 
Population with cardiovascular disease 
Population with  Type II Diabetes Mellitus 
Population with Metabolic Syndrome 
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Population with overweight/obesity 
 
Table 9. Moderators Unable to be Analyzed due to Lack of Reporting 
 
Moderators Unable to be Analyzed 
Proportion of Caucasian, Asian, Hispanic, Caribbean  
Oral contraceptive/hormone replacement therapy use 
Proportion of smokers 
Number of smokers 
Supplement use 
Alcohol intake 
Number of alcoholic drinks per week 
Type of alcohol consumption 
Amount of exercise per week 
Type of exercise 
Was dietary adherence monitored 
Were medications part of the intervention 
Total calories 
Dietary sodium intake 
Dietary potassium intake 
Unsaturated fat intake 
Saturated fat intake 
Cholesterol intake 
Fiber intake 
Servings of vegetables recommended  
Servings of dairy recommended  
Servings of wine recommended 
Servings of fish recommended 
Servings of olive oil recommended 
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Servings of legumes recommended 
Servings of meat recommended 
Servings of poultry recommended 
 
 
Table 10. Significant Associations – Weeks 
 
Outcome Diet 95% CI I2 P.value 
CRP BMD -0.6514 (-1.2934 to -
0.0094)* 
97.58 0.0467 
CRP MDOO -2.1013 (-3.2891 to -
0.9135)* 
97.58 0.0005 
IL6 BMD -2.0596 (-3.2698 to -
0.8493)* 
99.14 0.0009 
IL6 MDN -1.8007 (-3.5096 to -
0.0918)* 
99.14 0.0389 
TG BMD -2.9992 (-4.9145 to -
1.0839)* 
92.28 0.0021 
LDL MDN -1.2735 (-2.4291 to -
0.1179)* 
98.03 0.0308 
LDL MDOO -1.4883 (-2.6436 to -
0.3330)* 
98.03 0.0116 
Note: CRP, c-reactive protein; IL6, interleukin-6; VCAM, vascular cellular adhesion 
molecule; TG, triglycerides; LDL, low-density lipoprotein; *indicates significant results; I2 
represents the magnitude of heterogeneity; p.value represents significance of difference. 
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Table 11.  Significant Associations --- Females 
 
Outcome Diet 95% CI I2 P.value 
CRP BMD -0.9557 (-1.5542 to -
0.3571)* 
97.78 0.0018 
CRP MDOO -2.4291 (-3.7801 to -
1.0782)* 
97.78 0.0004 
IL6 BMD -2.2078 (-3.3139 to -
1.1016)* 
99.04 <.0001 
IL6 MDN -2.0668 (-3.7244 to -
0.4093)* 
99.04 0.0145 
ICAM MDN -9.9019 (-15.9789 to -
3.8248)* 
99.92 0.0014 
VCAM BMD -1.6574 (-2.7934 to -
0.5214)* 
98.62 0.0042 
VCAM MDN -3.2953 (-5.3489 to -
1.2417)* 
98.62 0.0017 
VCAM MDOO -2.7371 (-4.7556 to -
0.7186)* 
98.62 0.0079 
TG BMD -0.6336 (-0.9348 to -
0.3324)* 
92.28 <.0001 
LDL BMD -1.0553 (-1.6537 to -
0.4569)* 
97.56 0.0005 
LDL MDN -2.5194 (-3.8455 to -
1.1932)* 
97.56 
 
0.0002 
LDL MDOO -2.7329 (-4.0630 to -
1.4028)* 
97.56 <.0001 
HDL MDN 1.4951 (0.5751 to 
2.4151)* 
97.56 0.0014 
HDL MDOO 0.9567 (0.0683 to 
1.8452)* 
97.56 0.0348  
 
Note: CRP, c-reactive protein; IL6, interleukin-6; ICAM, intracellular vascular adhesion 
molecule; VCAM, vascular cellular adhesion molecule; TG, triglycerides; LDL, low-density 
lipoprotein; *indicates significant results; p.value represents significance of difference. 
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Table 12.  Significant Associations – Age 
 
Outcome Diet 95% CI I2 P.value 
CRP MDOO -2.9057 
(-5.6602 to -
0.1512)* 
97.82 0.0387 
VCAM BMD -91.6845 
(-163.8491* to -
19.5199) 
99.13 0.0128 
VCAM MDN -91.9121 
(-163.8968 to -
19.9274)* 
99.13 0.0123 
VCAM MDOO -91.3928 
(-163.3769 to -
19.4086)* 
99.13 0.0128 
 
 
Note: CRP, c-reactive protein; VCAM, vascular cellular adhesion molecule; TG, 
triglycerides; LDL, low-density lipoprotein; *indicates significant results; I2 represents the 
magnitude of heterogeneity; p.value represents significance of difference. 
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Table 13. Significant Associations – Region 
 
Outcome Diet 95% CI I2 P.value 
CRP BMD -2.5260 (-3.8809 to -
1.1711)* 
97.05 0.0003 
CRP MDN -2.9090 (-4.7087 to -
1.1093)* 
97.05 0.0015 
CRP MDOO -3.9153 (-4.7087 to -
1.1093)* 
97.05 <.0001 
ICAM MDN -11.6377 (-18.3046 to -
4.9707)* 
99.93 0.0006 
VCAM MDN -2.0563 (-3.9014 to -
0.2112)* 
99.27 0.0289 
TG BMD -1.2591 (-1.9250 to -
0.5931)* 
89.28 0.0002 
TG MDN -0.8348 (-1.6619 to -
0.0077)* 
89.28 0.0479 
TG MDOO -0.7134 (-1.3673 to -
0.0596)* 
89.28 0.0367 
LDL BMD -0.7551 (-1.2870 to -
0.2232)* 
96.88 0.0054 
LDL MDOO -1.0078 (-1.9416 to -
0.0741)* 
96.88 0.0344 
 
Note: CRP, c-reactive protein; intracellular vascular adhesion molecule; VCAM, vascular 
cellular adhesion molecule; TG, triglycerides; LDL, low-density lipoprotein; *indicates 
significant results; I2 represents the magnitude of heterogeneity; p.value represents 
significance of difference.. 
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Table 14. Significant Associations – Population Recruitment 
 
Outcome Diet 95% CI I2 P.value 
CRP MDOO -2.3576 (-4.1607 to -
0.5546)* 
97.86 0.0104 
ICAM MDN -7.6589 (-13.5122 to -
1.8057)* 
99.95 0.0103 
VCAM BMD -1.5763 (-2.8827 to -
0.2700)* 
99.27 0.0186 
VCAM MDN -2.0563 (-3.9014 to -
0.2112)* 
99.27 0.0289 
LDL BMD -1.0943 (-2.1792 to -
0.0095)* 
98.10 0.0480 
LDL MDN -1.7842 (-3.3721 to -
0.1963)* 
98.10 0.0276 
LDL MDOO -1.9969 (-3.5858 to -
0.4080)* 
98.10 0.0138 
 
 
Note: CRP, c-reactive protein; intracellular vascular adhesion molecule; VCAM, vascular 
cellular adhesion molecule; TG, triglycerides; LDL, low-density lipoprotein; *indicates 
significant results; I2 represents the magnitude of heterogeneity; p.value represents 
significance of difference. 
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Table 15. Significant Associations – Intervention Level 
 
 
Note: CRP, c-reactive protein; VCAM, vascular cellular adhesion molecule; TG, 
triglycerides; LDL, low-density lipoprotein; *indicates significant results; I2 represents the 
magnitude of heterogeneity; p.value represents significance of difference. 
  
Outcome Diet 95% CI I2 P.value 
CRP MDOO -2.2663 (-
3.5380 to -
0.9946)* 
97.84 0.0005 
VCAM MDN -2.0044 (-
3.5135 1 to -
0.4953)* 
99.08 0.0092 
TG BMD -0.6762 (-
1.1267 to -
0.2258)* 
92.14 0.0033 
LDL BMD -1.4003 (-
2.4459 to -
0.3547)* 
98.09 0.0087 
LDL MDN -1.7488 (-
3.1393 to -
0.3582)* 
98.09 0.0137 
LDL MDOO -1.9578 (-
3.3444 to -
0.5712)* 
98.09 0.0057 
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Table 15. Significant Associations – MQ  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: CRP, c-reactive protein; IL6, interleukin-6; LDL, low-density lipoprotein; *indicates 
significant results; I2 represents the magnitude of heterogeneity; p.value represents 
significance. 
 
 
 
 
  
Outcome Diet 95% CI I2 P.value 
CRP MDOO -2.7137 
(-5.3348 
to -
0.0926)* 
97.89 0.0424 
IL6 BMD -7.8048 
(-
13.6727 
to -
1.9369)* 
99.22 0.0091 
IL6 MDN -7.7562 
(-
13.9929 
to -
1.5194)* 
99.22 0.0148 
IL6 MDOO -7.0516 
(-
13.2876 
to -
0.8156)* 
99.22 0.0267 
LDL MDN -2.9113 
(-5.6745 
to -
0.1482)* 
98.08 0.0389 
LDL MDOO -3.1220 
(-5.8825 
to -
0.3616)* 
98.08 0.0266 
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Figure 2. Forest Plot for Total CVD Events 
 
 
 
Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 
represents the weighted mean effect size for the outcome.  
Figure 3. Forest Plot for Myocardial Infarction  
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Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 
represents the weighted mean effect size for the outcome.  
Figure 4. Forest Plot for CVD related Events 
 
Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 
represents the weighted mean effect size for the outcome.  
 
Figure 5. Forest Plot for C-reactive Protein 
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Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 
represents the weighted mean effect size for the outcome.  
Figure 6. Forest Plot for Interleukin 6 
 
Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 
represents the weighted mean effect size for the outcome.  
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Figure 7. Forest Plot for ICAM 
 
Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 
represents the weighted mean effect size for the outcome.  
 
Figure 8. Forest Plot for VCAM 
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Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 
represents the weighted mean effect size for the outcome.  
 
Figure 9. Forest Plot for TG 
 
Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 
represents the weighted mean effect size for the outcome.  
Figure 10. Forest Plot LDL 
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Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 
represents the weighted mean effect size for the outcome.  
 
Figure 11. Forest Plot HDL 
 
 
 
Note: Squares represent point estimates for each individual study; extended line shows 
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond 
represents the weighted mean effect size for the outcome.  
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Figure 12. Meta-regression Plot for VCAM -- Weeks 
 
 
 
B=-0.0615, p.value=0.0098, R2=44.32 
 
Note: Number of weeks is on the x-axis; Outcome of interest is on the Y-axis; B is the 
unstandardized beta represented amount of change in outcome per week of intervention; 
R2 indicates the percentage of variability for by length.   
 
Figure 13. Meta-regression Plot for HDL--Weeks 
 
 
 
B=-0.0615, p.value=0.0098, R2=44.32 
 
Note: Number of weeks is on the x-axis; Outcome of interest is on the Y-axis; B is the 
unstandardized beta represented amount of change in outcome per week of intervention; 
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R2 indicates the percentage of variability for by length.   
 
Figure 14. Risk of Bias Summary  
 
 
 
 
 
 
 
 
  76	
 
 
 
 
 
 
Appendix 
 
Appendix 1. Comprehensive Search Strategy Details 
 
PubMed (1940s to present) 
Terms were searched in all fields; however, field labels were used to restrict 
specific terms/phrases to the Medical Subject Headings [Mesh], publication type 
[pt] and journal name [ta] fields. 
 ("Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR 
"Mediterranean style diet" OR "Mediterranean style diets" OR "Diet, 
Mediterranean"[Mesh])  AND ("cardiovascular disease" OR "Cardiovascular 
Diseases"[Mesh] OR "cardiovascular diseases" OR "heart disease" OR "heart diseases" 
OR CVD OR CVDs OR "Hypertension"[Mesh] OR hypertension OR hypertensive* OR 
"high blood pressure" OR "Myocardial Infarction"[Mesh] OR "myocardial infarction" OR 
"myocardial infarct" OR "MI" OR "heart attack" OR "Stroke"[Mesh] OR stroke OR 
"Coronary Artery Disease"[Mesh] OR "coronary artery disease" OR "coronary arterial 
disease" OR "coronary heart disease" OR "Cerebrovascular Disorders"[Mesh] OR 
"Cerebrovascular Disorders" OR "cerebrovascular disease" OR "cerebrovascular 
diseases" OR "Atherosclerosis"[Mesh] OR atherosclerosis OR "Arteriosclerosis"[Mesh] 
OR arteriosclerosis OR "Peripheral Vascular Diseases"[Mesh] OR "peripheral vascular 
diseases" OR  "peripheral vascular disease" OR "peripheral angiopathy" OR "peripheral 
angiopathies" OR "Peripheral Arterial Disease"[Mesh] OR "peripheral arterial disease" 
OR "peripheral arterial diseases" OR "peripheral artery disease" OR "peripheral artery 
diseases" OR "Venous Thrombosis"[Mesh] OR "venous thrombosis" OR  "venous 
thromboses" OR "deep vein thrombosis" OR "deep vein thromboses" OR "Pulmonary 
Embolism"[Mesh] OR "pulmonary embolism" OR "pulmonary embolisms" OR 
"Dyslipidemias"[Mesh] OR dyslipidemia OR dyslipidemias OR 
"Hypercholesterolemia"[Mesh] OR hypercholesterolemia OR hypercholesterolemias OR 
"Aortic Valve Stenosis"[Mesh] OR "Aortic Valve Stenosis" OR "aortic valve stenoses" 
OR "aortic stenosis" OR "aortic stenoses" OR "Aneurysm"[Mesh] OR Aneurysm OR 
aneurysms OR Aneurism OR regurgitation OR prolapse) AND (("clinical"[tiab] AND 
"trial"[tiab]) OR "clinical trials as topic"[mesh] OR "clinical trial"[pt] OR random*[tiab] OR 
"random allocation"[mesh] OR "therapeutic use"[sh]) NOT  ("Case Reports"[pt] OR 
Comment[pt] OR Editorial[pt] OR Letter[pt] OR "case control"[ti] OR "case report"[ti] OR 
"case study"[ti] OR "case series"[ti] OR "Case-Control Studies"[Mesh] OR "Follow-Up 
Studies"[Mesh] OR "observational study"[ti] OR "prospective cohort"[ti] OR "cohort 
studies" [Mesh:NoExp] OR "cohort study"[ti] OR "Follow-Up Studies"[mesh] OR 
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"Retrospective Studies"[mesh] OR "non-randomized"[ti] OR "follow up study"[ti] OR 
rat[ti] OR rats[ti] OR mice[ti] OR mouse[ti] OR dog[ti] OR dogs[ti] OR cats[ti]) 
Results: 568 
 
 
 
 
 
 
EMBASE (via Scopus) (1823 to present) 
Limits: Article, review, conference papers, journals 
All terms (unless otherwise noted) were searched in "Article Title, Abstract, 
Keywords". Because of character restrictions in Scopus, this search was run in 
parts and assembled using the "Search history". 
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR 
"Mediterranean style diet" OR "Mediterranean style diets" 
AND 
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart 
diseases" OR CVD OR CVDs OR hypertension OR hypertensive* OR "high blood 
pressure" OR "myocardial infarction" OR "myocardial infarct" OR MI OR "heart attack" 
OR stroke OR "coronary artery disease" OR "coronary arterial disease" OR "coronary 
heart disease" OR "Cerebrovascular Disorders" OR "cerebrovascular disease" OR 
"cerebrovascular diseases" OR atherosclerosis OR arteriosclerosis OR "peripheral 
vascular diseases" OR  "peripheral vascular disease" OR "peripheral angiopathy" OR 
"peripheral angiopathies" OR "peripheral artery disease" OR "peripheral artery 
diseases" OR "peripheral arterial disease" OR "peripheral arterial diseases" OR "venous 
thrombosis" OR  "venous thromboses" OR "deep vein thrombosis" OR "deep vein 
thromboses" OR "pulmonary embolism" OR "pulmonary embolisms" OR dyslipidemia 
OR dyslipidemias OR hypercholesterolemia OR hypercholesterolemias OR "Aortic 
Valve Stenosis" OR "aortic valve stenoses" OR "aortic stenosis" OR "aortic stenoses" 
OR aneurysms OR Aneurism OR regurgitation OR prolapse  
AND  
Option 1:  (clinical AND trial)  
OR  
Option 2:  random* OR "therapeutic use" 
NOT 
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report" 
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case 
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR 
"cohort study" OR "retrospective study" OR "non-randomized" 
Results: 149 
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CINAHL (1981-present) 
All terms were searched in all fields (unless otherwise noted) 
Excluded: MEDLINE Records 
Limited: academic journals, journal article 
Due to database limitations, search was run in parts and assembled using the 
search history. 
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR 
"Mediterranean style diet" OR "Mediterranean style diets" 
AND 
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart 
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood pressure" OR 
"myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR "coronary artery 
disease" OR "coronary heart disease" OR "cerebrovascular disease" OR 
"atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular disease" OR "peripheral 
artery disease" OR "deep vein thrombosis" OR "pulmonary embolism" OR 
"dyslipidemia" OR "hypercholesterolemia" OR "aortic stenosis" OR "Aneurism" OR 
"regurgitation" OR "prolapse" 
AND 
Option 1: (clinical AND trial) 
OR  
Option 2: (MH "Clinical Trials+") OR "clinical trial" OR random* OR (MH "Random 
Assignment") OR "therapeutic use" 
NOT  
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report" 
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case 
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR 
"cohort study" OR "retrospective study" OR "non-randomized" 
 
Results :  40 
 
PsycINFO  (1872 to present) 
Limits: academic journals 
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Due to database limitations, search was run in parts and assembled using the 
search history. 
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR 
"Mediterranean style diet" OR "Mediterranean style diets" 
AND 
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart 
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood pressure" OR 
"myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR "coronary artery 
disease" OR "coronary heart disease" OR "cerebrovascular disease" OR 
"atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular disease" OR "peripheral 
artery disease" OR "deep vein thrombosis" OR "pulmonary embolism" OR 
"dyslipidemia" OR "hypercholesterolemia" OR "aortic stenosis" OR "Aneurism" OR 
"regurgitation" OR "prolapse" 
AND 
Option 1: (clinical AND trial) 
OR  
Option 2: (DE "Clinical Trials") OR "clinical trial" OR random* OR (DE "Random 
Sampling") OR "therapeutic use" 
NOT  
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report" 
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case 
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR 
"cohort study" OR "retrospective study" OR "non-randomized" 
 
Results: 14 
 
Academic Search Premier (1980s to present) 
Limit:  Scholarly (Peer Reviewed) Journals 
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR 
"Mediterranean style diet" OR "Mediterranean style diets" 
AND 
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart 
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood pressure" OR 
"myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR "coronary artery 
disease" OR "coronary heart disease" OR "cerebrovascular disease" OR 
"atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular disease" OR "peripheral 
artery disease" OR "deep vein thrombosis" OR "pulmonary embolism" OR 
"dyslipidemia" OR "hypercholesterolemia" OR "aortic stenosis" OR "Aneurism" OR 
"regurgitation" OR "prolapse" 
AND 
Option 1: (clinical AND trial) 
OR  
Option 2: (random* OR "therapeutic use") 
NOT  
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(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report" 
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case 
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR 
"cohort study" OR "retrospective study" OR "non-randomized" 
Results: 208 
 
 
Agricola (1970-present) 
Searched in "All Fields"  
Limits: academic journals 
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR 
"Mediterranean style diet" OR "Mediterranean style diets" 
AND 
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart 
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood pressure" OR 
"myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR "coronary artery 
disease" OR "coronary heart disease" OR "cerebrovascular disease" OR 
"atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular disease" OR "peripheral 
artery disease" OR "deep vein thrombosis" OR "pulmonary embolism" OR 
"dyslipidemia" OR "hypercholesterolemia" OR "aortic stenosis" OR "Aneurism" OR 
"regurgitation" OR "prolapse" 
AND 
Option 1: (clinical AND trial) 
OR  
Option 2: (random* OR "therapeutic use") 
NOT  
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report" 
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case 
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR 
"cohort study" OR "retrospective study" OR "non-randomized" 
 
Results: 40 
 
CAB Direct (1973-present) 
Limit to Document Type: Journal article and Evidence based research articles 
only 
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR 
"Mediterranean style diet" OR "Mediterranean style diets" 
AND 
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR "heart 
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood pressure" OR 
"myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR "coronary artery 
disease" OR "coronary heart disease" OR "cerebrovascular disease" OR 
"atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular disease" OR "peripheral 
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artery disease" OR "deep vein thrombosis" OR "pulmonary embolism" OR 
"dyslipidemia" OR "hypercholesterolemia" OR "aortic stenosis" OR "Aneurism" OR 
"regurgitation" OR "prolapse" 
AND 
Option 1: (clinical AND trial) 
OR  
Option 2: (random* OR "therapeutic use") 
NOT  
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case report" 
OR comment OR editorial OR letter OR "case control" OR "case study" OR "case 
series" OR "follow-up study" OR "observational study" OR "prospective cohort" OR 
"cohort study" OR "retrospective study" OR "non-randomized" 
 
Results: 0 results 
 
 
 
 
Appendix 2. Screening Form 
 
updated: 9/23/15                                                                                                              
Study ID:  
Coder: __________ 
Mediterranean Diet CVD Meta-Analysis Selection Criteria 
Inclusion Criteria 
Trials MUST match all of these criteria: 
 
 
Exclusion Criteria  
Studies CANNOT include any of the 
following: 
 
Pre- AND Post-intervention design 
[  ] 
 
Mediterranean diet (as a whole, for 
example, not just olive oil) for at least 
one of the  interventions. Can also be 
described as Mediterranean-style diet, 
hypocaloric Mediterranean diet, etc. 
[  ] 
Cardiovascular disease events (ex: 
MI, CVD related deaths…etc). 
[  ] 
 
 
  
Animal Models [  ] 
Surveys [  ] 
Commentary [  ] 
Symposium Sessions [  ] 
Research Support  [  ] 
Letters [  ] 
Position Paper/Viewpoint [  
] 
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Inflammatory Biomarkers (CRP, IL6, 
ICAM, VCAM) 
[  ] 
                
Review [  ] 
Guidelines [  ] 
Epidemiologic Studies [  ] 
Cross-sectional Studies [  ]  
Observational Studies [  ] 
Olive oil only [  ] 
Wine only [  ] 
Fish only [  ] 
Antioxidants only [  ] 
 
  
  
 
 
Appendix 3. Comprehensive Coding Form and Coding Manual (updated July 2015) 
 
CODER________    Coder (Julia=1, Marisa=2, Other=3) 
 
Study Information 
ID _______   Study ID (first 3 letters of 1st author’s last name & unique ID#: Pescatello= PES001), ___________________ 
(Last name, Yr)  
PUB_YR  ________   Publication year (consider this missing if unpublished) 
DATA  ________   Estimated year of data collection (earliest date for data collection or manuscript 
submission/publication;  
   if unpublished and date unknown, use year manuscript was acquired; for dissertation or thesis, use year)  
 
LANG ________   Language of report 1=English     2=Spanish     3=Japanese     4=Other, specify: 
_________________________ 
SOURCE________   Publication Type 1=journal    2=book    3=thesis/dissertation    4=conference paper    5= 
unpublished 
     
SCORE ________   Impact Score of the Journal (use ISI Web of Knowledge journal citation reports) 
JOURNAL NAME _________________________________________________________________________ 
PUBMED NAME/ ABBR. _________________________________________________________________ 
 
FUNDING SOURCE_______   1= Gov’nt (i.e., CDC, NIH, etc)     2= Academic/University     3= Private     4= Multiple 
For all, specify source/grant: 
_____________________________________________________________________________
_____ 
_____________________________________________________________________________
_________ 
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NOTE_STUDY________ study notes (make note of multiple arms; ex. MD vs. low fat vs. low carb + MD vs. CONTROL): 
_____ 
_________________________________________________________________________________________________ 
 
Sample Characteristics (proportion: 0.0- 1.0) Note: IF ethnicity is reported, ETH_EST will be == 0 
 
ETH ________   Ethnicity reported?    1 = yes; 0 = no   
PROP_WH ______ Proportion White; whole #____   PROP_BLK ______ Proportion Black/ 
whole #____  
PROP_ASIAN ______ Proportion Asian/ whole #____   PROP_MIX ______ Proportion Mixed 
(other)/ whole #____ 
PROP_HISP ______ Proportion Latino/Hispanic/ whole #____  
PROP_CARIB ______ Proportion Caribbean/ whole #____  
ETH_EST  ________   Assumed ethnicity (0= n/a, 1= White, 2= Asian, 3= Black, 4= Unreported, 5= Hispanic/Latino) 
 
NUM_FemCON  ________   # of Females in Sample; Proportion 
(##$%&'$( )*)&'	(&%,'$):___________ 
NUM_FemIN1  ________   # of Females in Sample; Proportion 
(##$%&'$( )*)&'	(&%,'$):___________ 
NUM_FemIN2  ________   # of Females in Sample; Proportion 
(##$%&'$( )*)&'	(&%,'$):___________ 
NUM_FemIN3 ________   # of Females in Sample; Proportion (##$%&'$( )*)&'	(&%,'$):___________ 
 
REGION________   Location of sample (if unreported, use location of first author as estimate of study location) 
1=American city: __________________ US_ZIP_______   2=other US region (city= 
unreported):_____________ 
3=Canada (city: _______________________)    4=Europe (city: 
_______________________)  
5=South/Central America, Mexico, Caribbean (city: _______________) 6=Africa (city: 
_______________________) 
7=Asia (city: Osaka, Japan)      8=Australia (city: 
_______________________) 
  
POP ________ Population 0=not reported  1=school/college     2=community (senior center, flyers, etc.) 
________________  
 3= clinical/hospital (e.g., cardiac rehab, outpatient clinic, etc.) _______________________________ 
  
NOTE_RECRUIT Notes on recruitment/ sample location __________________________________________________ 
 
Risk Characteristics- report values of baseline data (check methods or descriptive tables) KEEP DATA SEPARATE FOR 
GROUPS  
 
TOTAL_POP ________   Reported as total sample? (1=yes, 0=no) *if data is collapsed, not separate for groups, chose YES
  
Characteristic 
CONTROL/ 
COMPARISON 
n=____  
(total sample)  
IN1 n=____ 
(total sample), 
specify 
intervention_____
_ 
IN2 n=____ 
(total sample), 
specify 
intervention_______
_   
IN3 n=____ 
(total sample), 
specify 
intervention_____
_   
 Mean age (years) AGE  AGE  AGE  AGE  
SD for age (years) AGE_SD AGE_SD   AGE_SD   AGE_SD  
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Characteristic 
CONTROL/ 
COMPARISON 
n=____  
(total sample)  
IN1 n=____ 
(total sample), 
specify 
intervention_____
_ 
IN2 n=____ 
(total sample), 
specify 
intervention_______
_   
IN3 n=____ 
(total sample), 
specify 
intervention_____
_   
Known disease/ chronic 
conditions  
0= Healthy  
3= CVD(s) (i.e., CAD, 
PAD, HF, MI) 
4= Stroke 5= 
Diabetes 
6= MetS  7= 
Arthritis 
8= Dyslipidemia  9= 
Obesity  
10= Other, 
specify:______________
_ 
11= Multiple, specify 
#s:___________ 
DISEASE DISEASE DISEASE DISEASE 
If disease: report prop. & 
number  
if “healthy” denote 0= 
n/a; if missing=“.” 
PROP_DISEAS
E  
NumberDisease 
PROP_DISEASE  
NumberDisease 
PROP_DISEASE  
NumberDisease 
PROP_DISEASE  
NumberDisease 
Medication use  (0=no, 
1= yes) 
MED MED MED MED 
If yes, report prop & 
number; if no meds, 
use 0=NA (if missing 
=“.”)  
PROP_USE 
NumberMED 
PROP_USE 
NumberMED 
PROP_USE 
NumberMED 
PROP_USE 
NumberMED 
Medication Type (if no 
meds= 0)  
1= β Blockers 2= 
Nitrates 
3= Ca+2 Channel 
Blockers 
4= Angiotension 
Converting Enzyme 
(ACE) Inhibitors 
5= Diuretics 6= 
Vasodilators  
7= NSAIDs 8= 
Aspirin 
9= Statins
 10=Other, 
specify:  
11= Multiple, specify: 
________ 
MED_TYPE MED_TYPE MED_TYPE MED_TYPE 
BP Medication use (1= 
yes, 0=no)  
If unreported == “.” 
BPMedUse BPMedUse BPMedUse BPMedUse 
If yes, report prop. & 
number  
(if “no”=0, NA; if 
missing denote=“.”)  
BPMedProp 
BPMedNumber 
BPMedProp 
BPMedNumber 
BPMedProp 
BPMedNumber 
BPMedProp 
BPMedNumber 
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Characteristic 
CONTROL/ 
COMPARISON 
n=____  
(total sample)  
IN1 n=____ 
(total sample), 
specify 
intervention_____
_ 
IN2 n=____ 
(total sample), 
specify 
intervention_______
_   
IN3 n=____ 
(total sample), 
specify 
intervention_____
_   
If taking meds, is BP 
controlled?  
yes= 1, if SBP≤140 OR 
DBP≤90; no= 0, 
SBP>140 OR DBP>90  
(*if no BP use == NA) 
BPControl BPControl BPControl BPControl 
LIFESTYLE VARIABLES  
Oral Contraceptive 
(0=no, 1= yes) 
OR Hormone 
replacement therapy 
OC_USE 
HRT_USE 
OC_USE 
HRT_USE 
OC_USE 
HRT_USE 
OC_USE 
HRT_USE 
Smokers/smokers (≤6 
months) (0=no,1=yes; 
if missing = “.”) 
SMOKE SMOKE SMOKE SMOKE 
If yes, report smoker 
prop. & number 
PROP_SMOKE 
NumberSMOKE  
PROP_SMOKE 
NumberSMOKE 
PROP_SMOKE 
NumberSMOKE  
PROP_SMOKE 
NumberSMOKE  
Nutritional 
Supplements 
Permitted? (0=no, 
1=yes) 
SUPP SUPP SUPP SUPP 
If yes, specify type TYPE TYPE TYPE TYPE 
Consume Alcohol? 
(0=no, 1=yes) ALC ALC ALC ALC 
If yes, how many 
drinks/week? AMT AMT AMT AMT 
If yes, what type of 
alcohol? ALCTYPE ALCTYPE ALCTYPE ALCTYPE 
Amount of exercise 
per week (in min) EX EX EX EX 
Type of exercise (e.g., 
cardio, strength 
training) 
    
 
NOTE_RISK Notes on risk characteristics relevant to coding 
_____________________________________________ 
 
Methods & Design 
CON_GRP ________    Type of control group used 
 1= random assignment of individuals to conditions including a non-diet control group, 
specify_________________ 
 2= random assignment of individuals to conditions including non-diet control session 
 3= random assignment of individuals to non-MD condition/diet 
 4= random assignment of individuals a non-diet control group 
  5= other, specify: ______________________________________________________________________
  
 
Experiment/ Intervention Conditions 
 
EXPERIMENT________ INTERVENTIONS/EXPERIMENTAL CONDITION(S)  
 
1= non-diet control/comparison + 1 intervention  2= non-diet control/comparison + 2 interventions
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3= non-diet control/comparison + 3 interventions 
 
4= diet control/comparison + 1 intervention  5= diet control/comparison + 2 interventions  
  
6= diet control/comparison + 3 interventions  7= crossover design    
  
 
EXP_SETTING________ Setting of Intervention(s) 1= hospital       2= clinic       3= academic/research lab       4= 
fitness center, gym 
5= Other, specify: ___________________________________                6= multiple, specify:__________  
  
DIET_MONITOR________   Was diet adherence monitored? (0= none; 1= yes) If yes, specify: 
_______________________________________________________________________________________________
___________ 
 
BEHAV_TECH__________Behavioral technique/monitoring system used?(0=none, 1=yes) If yes, specify-
_______________________________________________________________________________________________
___________ 
Examples: positive reinforcement/contingency management, exercise & lifestyle information/lectures; PA logs, etc.  
 
INTER_LVL________ Level of intervention or supervision used in the study 
1=primarily 1-on-1      2=small group processes (supervisor & group members)    3= supervised session(s)  
4= unsupervised session(s)     5=incentive (payment based on sessions attended)     
6= multiply, specify #’s:_____________________________  
 
NOTE_EXP & METHODS Notes related to study design & delivery of intervention: 
____________________________
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Diet Intervention Characteristics    
DIET CHARACTERISTICS 
CONTROL/ 
COMPARISON IN1 IN2 IN3 
LENGTH___(in weeks)  LENGTH__ LENGTH__ LENGTH__ LENGTH__ 
WTGain/WTLoss___ 
(1=loss, 2=gain, 3=maintain, 
4=unspecified) 
WTGain/WTLoss___ 
 
WTGain/WTLoss___ 
 
WTGain/WTLoss___ 
 
WTGain/WTLoss___ 
 
PART_LOST # of drop outs      
ADHERENCE (report %) If 
reported as # of sessions 
completed, use== 
(.*%,'$)$/	($((0*1()*)&'	($((0*1(  x 100) 
    
Were medications used as 
part of the intervention? 
(0=no, 1=yes) 
MEDS__ MEDS__ MEDS__ MEDS__ 
If yes, specify 
1= β Blockers 2= Nitrates 
3= Ca+2 Channel Blockers 
4= Angiotension Converting 
Enzyme (ACE) Inhibitors 
5= Diuretics 6= 
Vasodilators  
7= NSAIDs 8= Aspirin 
9= Statins 10=Other, 
specify:  
11= Multiple, specify: ________ 
MED__TYPE  MED__TYPE MED__TYPE MED__TYPE 
DIET__TYPE 
(1=MedDiet, 2=low-fat, 3=high 
protein, 4=low-carb, 5=other, 
specify) 
DIET__TYPE  DIET__TYPE DIET__TYPE DIET__TYPE 
Provision of Med Diet Foods? (0=no, 1=yes) 
If yes, type and amount___ 
1=olive oi (amt:____) 
2=nuts (amt:___) 
3=fruits (amt:___) 
4=fish (amt:___) 
5=dairy (amt:___) 
6=multiple 
    
Diet specification reported as a distribution of macronutrients? (0=no, 1=yes) 
If yes, specify 
PropCHO___ 
PropSatFAT___ 
PropTotFAT___ 
PropPRO___  
PropCHO___ 
PropSatFAT___ 
PropTotFAT___ 
PropPRO___ 
PropCHO___ 
PropSatFAT___ 
PropTotFAT___ 
PropPRO___ 
PropCHO___ 
PropSatFAT___ 
PropTotFAT___ 
PropPRO___ 
PropCHO___ 
PropSatFAT___ 
PropTotFAT___ 
PropPRO___ 
KCAL_TOTAL_BASE(kcal/day) 
KCAL_TOTAL_END (kcal/day) 
KCAL_Rx Prescribed kcals per 
day    
KCAL_REPORT Reported 
kcals per day  
____________ 
___________ 
____________ 
____________ 
____________ 
___________ 
____________ 
____________ 
____________ 
___________ 
____________ 
____________ 
____________ 
___________ 
____________ 
____________ 
Energy restriction (kcal or %)
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DIET CHARACTERISTICS 
CONTROL/ 
COMPARISON IN1 IN2 IN3 
KCAL_RES (unit= kcal) OR 
RES_PERCENT (%) 
SOD_INTAKE (mg/day)     
POT_INTAKE (mg/day)     
FAT_INTAKE (g/day)    
Unsaturated: FAT_UNSAT 
          Saturated: 
FAT_SAT           
Cholesterol: FAT_CHOL 
____________ 
____________ 
____________ 
____________ 
____________ 
____________ 
____________ 
____________ 
____________ 
____________ 
____________ 
____________ 
Dietary Fiber Intake (g/day)    
FIB_INTAKE 
    
Servings/week: Fruit and/or 
Vegetables    
VEG_SER 
    
Servings/week: Dairy
 DAIRY_SER 
    
Servings/week: Wine   
WINE_SER 
    
Servings/week: Whole Grains  
GRAIN_SER 
    
Servings/week: Fish  
FISH_SER 
    
Servings/week: Olive Oil   
OIL_SER 
    
Servings/week: Nuts   
NUTS_SER 
    
Servings/week: Legumes   
LEG_SER 
    
Servings/week: 
Red/processed meat   
MEAT_SER 
    
Servings/week: Poultry   
POUL_SER 
    
Dietary Compliance & Counseling 
DI_COMPLIANCE   Was 
Dietary compliance assessed? 
0= No; 1= Yes) 
    
If yes, specify: 
(1=FFQ, 2=Food journal, 
3=phone interviewing, 4=24 hr 
recall, 5=other,specify___)  
    
Was diet adherence 
measured pre, during, or post 
intervention? (1=pre, 2=during, 
3=post, 4=pre,during, and post, 
5=pre and post, 6=not reported) 
    
Is a scale used to measure 
adherence? (0=no, 1=yes) 
    
If yes, specify type of scale 
used___ 
    
DI_COUNSELING   
Participation in dietary 
counseling? 0= no; 1= yes 
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DIET CHARACTERISTICS 
CONTROL/ 
COMPARISON IN1 IN2 IN3 
If Dietary Counseling was 
provided, report: 
COUNSEL_HR   hours per 
week 
COUNSEL_SESS sessions per 
week   
____________ 
 
____________ 
____________ 
 
____________ 
____________ 
 
____________ 
____________ 
 
____________ 
DIET_TOPIC  If Dietary 
Counseling was provided, 
briefly state topics covered 
 
 
   
QoL Was Quality of Life (QoL) 
assessed? 0=no, 1=yes, if yes, 
report tool or scale 
    
NOTE_DIET  Report here any notes relevant to the dietary intervention, counseling, implementation, etc.    
 
 
 
# of follow-ups     
Interval of follow-ups     
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MEDITERRANEAN DIET: 
Meta-Analytic Projects 
 
 
 
 
 
 
Standard Operating 
Procedures (SOP) Coding 
Form Manual  
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STUDY ID create unique study ID using the first three letters of 1st author’s last name, and 
number to denote if multiple ID exists. For example, author is Pescatello= PES001. The 
number 001 denotes that it the first article with that study ID.  
 
PUB_YR: Publication year  
 
DATA: Record the earliest date for data collection, manuscript submission or acceptance for 
publication. If there is a date of manuscript submission/ acceptance use the publication date. If it 
is unpublished and the date is unknown, denote as “.” 
 
LANG: language of report 
 
SCORE: Use the ISI Web of Knowledge journal citation report for score (access through 
www.lib.uconn.edu) 
• Go to “research assistance” 
• Choose “research databases” – choose database by name & type in “Web of Science” 
• Choose “additional resources” and “journal citation report” 
• Under “select an option”- choose “search for a specific journal” and submit 
• Click on “view list of full journal titles;” copy and paste journal name into search 
• Record the number under “Impact Factor”   
 
Note: If the journal is not found on ISI Web of Knowledge, you can check the journal’s home 
page. If you can find the impact factor score there-use it. Make sure you note in (V8) where 
information was found; if still unable to retrieve score, denote as “.” 
 
JOURNAL NAME: Record the full name of the journal here (i.e., American Journal of Sports 
Medicine) 
PUBMED NAME: Record the PubMed abbreviated name of the journal here (i.e., Am J Sports 
Med) 
 
NOTE_STUDY: Record any relevant notes here about above variables.  
 
SAMPLE CHARACTERISTICS: If the following variables are reported in the manuscript, record 
as a proportion; values range from 0.0- 1.0.  
 
ETH: Record the ethnicity/ race of subjects as a proportion. For example: If article reports, 
“subjects were all white men” the PROP_WH would be 1.0 and the remaining ethnicity 
classifications would be 0.0. However, if 18% is reported for Caucasian (or white) ethnicity, the 
proportion would be 0.18. If not explicitly stated, denote as MISSING (“.”) 
 
ETH_EST=Ethnicity estimate: when ethnicity is unreported or missing ethnicity will be 
assumed White if study was performed in Europe, Australia, or New Zealand; Asian if 
conducted in Asia; and Black if conducted in Africa, Hispanic if conducted in Brazil, Mexico.  If 
location of study is not reported in methods section, use the location of the first author’s 
affiliation (i.e., the university or clinical institution author is a part of). Note: IF ethnicity is 
reported (i.e., values were recorded for V9), then ETH_EST will be noted with “0” 
indicating it is not applicable. 
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NUM_FemCON, NUM_FemIN1 (all the way to NUM_FemIN3): Record the number of females 
that were in each of the study groups (i.e., intervention group). If there is only a diet + control 
design, leave the other variables blank or cross out. However, if multiple interventions exist (i.e., 
control + >1 diet groups), include # of females for each of the specific intervention and use 
all the way to NUM_FemIN3 if needed.  
 
REGION: Record the region of where the sample came from with one of the 8 codes. If the 
region is not included in the methods, use the location of the first author’s affiliation (i.e., the 
university or clinical institution author is a part of). 
 
US_ZIP: If the location is not provided in the article, use the zip code of first author’s affiliation 
(i.e., the university or clinical institution author is a part of). 
 
POP: If available, report population; 1=school or college OR 2= community. If patients were 
specifically recruited from a clinical setting or community (i.e., cardiac rehabilitation program, 
outpatient clinic, senior citizen center, local community center, etc.), make sure to specify.  
If population is not described, denote missing with “0.” For example, if authors report “15 
healthy men and women were recruited for the study,” this would not be describing the 
population and would be coded as 0.  
 
NOTE_RECRUIT: make any notes on recruitment 
 
RISK CHARACTERISTICS -report values provided for baseline sample data. This 
information is commonly reported in either 1) the methods section (written in text) OR 2) in a 
baseline/ descriptive table.  Be careful to note if the data is reported with SD or SEM. Record 
data in the way it is presented (mean±SD or mean±SEM) but change on sheet if SEM (just 
scratch SD and put SEM). If SEM is used, make sure this is very clear!  
 
TOTAL_POP: If information is provided for each intervention group separately and not in 
aggregate form (i.e., mean of total sample), choose “0= no” and use the existing format on 
sheet (i.e., enter into separate columns). If reported as total sample (i.e., aggregate form), 
choose “1=yes” and only use one column to record data. If article has >2 groups and 
reports data for each intervention (i.e. control group, low, moderate, vigorous intensities) use 
additional columns in table. 
NOTE: For n value, this corresponds to the number in sample you are working with (i.e., either 
total sample or for the specific intervention group).  
 
RISK CHARACTERISTIC TABLE:  all values should be recorded as metric (i.e., cm, kg). 
Any values that are missing, denote with “.” 
Use intervention columns to compare multiple groups if there is no true control.  
 
 DISEASE: If text describes subjects as “healthy,” “normotensive,” or “normal BP,” choose 0= 
subjects were free of disease(s)/ chronic condition(s). If article has clinical population, you may 
have more than >1 condition and/ or disease. If all conditions are represented in list, choose 
9=multiple and record the specific #s. If there is condition that is not included in the list, choose 
8=other and record specifically. 
1= Pre-Hypertensive is defined as, SBP 120-139 mmHg Or DBP 80-89 mmHg. 
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2= Hypertension Stage 1: SBP 140-159 mmHg Or DBP 90-99 mmHg, Stage 2: SBP ≥160 
mmHg Or DBP ≥100 mmHg (ACSM’s Guidelines for Exercise Testing and Prescription, 8th 
Edition). 
 
INFLAMMATION: If authors report that inflammation was measured, denote "1" and specify 
biomarkers/cytokines. If authors do not report measurement of inflammation, denote "0." 
 
CARDIAC EVENTS MEASURED: If authors report measurement of cardiac events, denote 
number corresponding with events. Report prop and or number if reported. Record how it is 
measured if it is not in proportion and number of events.  
 
For BP status, only record hypertension or pre-hypertension here IF author has classified 
population. DO NOT CLASSIFY BASED ON ORIENTATION BP VALUES. NOTE. If there is no 
mention about cardiovascular diseases or chronic conditions and they are not described as 
“healthy” denote missing information with “.” DO NOT ASSUME HEALTHY POPULATION.  
 
MED: If authors report that subjects were not taking any medications, choose “0.” If there is no 
mention of medication or medication use, code “.” indicating missing information. If article states 
medication use, continue to fill in PROP_USE and WholeNumberUse. IF the study reports 
medication use but DOES NOT report number of individuals using medication, report missing 
with “.” If article states that “medication use and dosage did not change during intervention,” 
chose 1=yes for medication use. If article states that medication was discontinued 4 weeks prior 
to intervention (i.e., wash out period), choose 0= no for medication use. 
 
MED_TYPE: if there is no medication use, code 0. If article has clinical population, you may 
have more than >1 medications. If all medications are represented in list, choose 9=multiple and 
record the specific #s. If there are medications used that are not included in the list, choose 
8=other and record specifically. 
 
BPMedUse: If MED is “yes,” report if BP medication specifically is taken; if MED was “no” code 
as 0.  
If MED was a “yes,” BUT article does not include a list of medications used and you cannot 
determine if BP agents were included, denote as not reported with “.”  
If BPMedUse is “yes,” fill in as much information as possible for BPMedProp, BPMedNumber 
and BPControl. If subjects are taking BP Meds their BP should be “controlled,” defined as a 
SBP ≤140 mmHg OR DBP ≤90 mmHg—it does not have to be both, just satisfying either the 
SBP or DBP cut point. 
  
Oral Contraceptive (OC) or Hormone Replacement Therapy (HRT) use: Report whether 
Oral contraceptives, birth control, or HRT were taken by female subjects during the study. If yes 
denote “1.” If no denote “0.” If all men subjects, chose=0. 
 
Lifestyle variables (i.e., smoking years, packs/yr; EtOH or alcohol consumption; caffeine 
consumption, etc.) are often not reported. Denote missing with “.” and make not of 
unreported lifestyle data in V79 NOTE_RISK (can record as “lifestyle variables = missing 
data”). 
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SMOKING: Report if the study sample included individuals who were currently smoking, or had 
a history of smoking. If yes denote “1,” if no denote “0;” if unreported or history of smoking is not 
disclosed in either study eligibility criteria (methods) or baseline data table denote missing “.”  
 
NUTRITIONAL SUPPLEMENTS Nutritional supplements allowed during intervention (not as 
part of the intervention).  If nutritional supplements were allowed during the intervention, indicate 
with 1=yes.  If nutritional supplements is excluded from the list of “approved” supplements, 
indicate with 0=no.  If there was no mention of nutritional supplements, denote with “.”.   
 
SUPPLEMENT TYPE 1=Fish oil, 2=Vitamin D, 3=MVI, 4=Calcium, 5=Other, specify:_________ 
 
ALCOHOL If participants do not drink alcohol, chose 0=no, if no mention of alcohol in the article 
denote with “.”. 
 
DRINKS/WEEK Report number of drinks/week.  If participants do not drink alcohol or alcohol 
was not mentioned in the article, denote with “.”. 
 
TYPE OF ALCOHOL Indicate which type of alcoholic beverage the participants report to 
consume.  If more than one type chose “4=multiple” and indicate the number associated with 
the consumed beverage.  If participants consume another type of alcohol, chose “5=other” and 
specify the type of alcohol.  If the type of alcohol is not mentioned or participants do not 
consume alcohol denote with “.”.   
1 = Beer 
2 = Wine 
3 = Liquor 
4 = Multiple, specify which numbers apply: ________ 
5 = Other, specify: _______ 
 
EXERCISE Indicate amount of exercise participants engaged in as min/week.  If not reported, 
denote with “.”. 
 
EXERCISE TYPE 1=cardio, 2=strength training, 3=stretching/yoga, 4=other, specify_____ 
 
NOTE_RISK: Record any additional information about data in table. 
  
Methods & Design 
 
CON_GRP: describes type of control group used in study. 
1= non-diet control group (study includes 2 separate groups of people, comprising a diet group 
and a control group), specify 
2= non-diet control session (study includes same individuals who perform both a diet 
intervention and a control session; more common in acute exercise) 
3= random assignment of individuals to non-MD condition/diet 
4=random assignment of individuals to a non-diet control group 
5= other, specify- if there was a non-diet control group (or session) used that involved a 
cognitive task, stress management, coping skills, etc. note it here 
 
 	 96	
EXPERIMENT: describes study design (i.e., parallel or repeated measure or cross-over design). 
Independent groups refer to a parallel study design. For example, there are 3 groups: a 
control group (non-diet), a Med diet group, and a low-fat diet group. The groups are 
independent of one another; they stay in the same group for the entire intervention. Independent 
groups are commonly found in training studies (i.e., chronic exercise). Non-independent 
groups refer to a repeated measure or cross-over study design. For example, there are 3 
conditions: a control session (non-diet), a Med diet group, and a low-fat diet group. Each person 
in the intervention will complete each condition serving as their own control. Non-independent 
groups are commonly found in acute studies (i.e., a single exercise bout). A crossover design 
assigns subjects to each intervention group for a period of time (ex: 4 wks crossover design with 
3 dietary conditions: non diet (control), Med Diet, and LF group. each subject will be on each 
diet for 4 wks with washout period). 
 
EXP_SETTING Indicate setting. 1= hospital, 2=clinic, 3=academic/research lab, 4=fitness 
center/gym, 5=other, specify, 6=multiple, specify.  
 
DIET MONITOR 0=no, 1=yes.  Indicate is diet adherence was assessed using food record, food 
frequency questionnaire, Med Diet score, etc. 
 
BEHAVIOR 0=no, 1=yes. If yes, specify. (examples: positive reinforcement, contingency 
management diet logs, motivational interviewing, cognitive dissonance, health belief model, 
etc.) Not food logs. Only if authors specify certain behavior technique.  
 
INTER_LVL: For acute studies specifically, unless author explicitly states exercise occurred in a 
group setting/ session- answer 3= supervised. If multiple apply, choose 5= multiple and specify. 
For primary one-on-one (=1), choose when study explicitly states individual counselling 
sessions or when exercise sessions are conducted with a personal trainer. 
 
NOTES_EXP & METHODS make any notes pertaining to experiment design and or methods. 
 
LENGTH Report length of intervention in weeks.  
 
WTGain/WTLoss Indicate whether the intervention was intended for weight gain, weight loss, 
or weight maintenance. 
 
PART_LOST Report the number of participants that dropped out from the study in each group.  
Add # of dropouts if various numbers are stated for different parts of the intervention.  
 
ADHERENCE (assessment of study completion): Record exercise adherence (i.e., the 
number of sessions completed during intervention) as a percent value, (234567879	:7::;3<:838=6	:7::;3<: ) x 100  
 
For control groups, use 100% adherence unless explicitly stated by study that subjects in the 
control group were lost during the intervention (i.e., due to sickness, moving, etc). 
 
MED_USE Report whether or not medications were used as part of the intervention. 
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YES_MEDS If medications were used as part of the intervention, specify which medication 
type(s) was used. 
 
DIET_TYPE Indicate what type of diet the participants in each group followed.  If one group 
followed a low-carb Mediterranean Diet that would fall in the “5=other” category and specify. 
 
PROVISION OF FOODS Were any specific foods provided to the participants? 0=no, 1=yes. 
 
IF yes, Type and Amount Indicate type and amount of foods provided to participants. 
 
DIET_MACROS Was the diet reported as a distribution of macronutrients? 0=n0, 1=yes. 
 
Specify Macro Distribution 
 
KCAL Please indicate total Kcals consumed, Total Kcals the participants were “prescribed”/told 
to consume each day, and total kcals that participants reported that they consumed.  If one of 
these components is not reported, denote with “.”. 
 
ENERGY RESTRICTION If calories were restricted for any group, report the Kcal restricted 
(kcal deficit per day) and/or the percent that energy was restricted.  If not reported, denote with 
“.”. 
 
SOD_INTAKE Report sodium intake in mg/day. 
 
POT_INTAKE Report potassium intake in mg/day. 
 
FAT_INTAKE Report all fat categories in g/day (from narrative). 
 
FIB_INTAKE Report dietary fiber intake in g/day. 
 
SERVINGS/WEEK For the following sections please report # of servings per week of each food.  
If not reported, denote with “.”. 
 
DI_COMPLIANCE Was dietary compliance assessed? 0=no, 1=yes.   
 
SPECIFY COMPLIANCE 0=no, 1=food frequency questionnaire, 2=food journal/diary, 3=phone, 
4=24 hr recall, 5=other, specify.  
 
ADHERENCE MEASURED 0=no, 1=pre, 2=during, 3=post, 4=pre, during, and post, 5= pre and 
post, 6= not reported. 
 
SCALE USED Examples of a scale to measure adherence would be the Mediterranean Diet 
Score. 
 
SPECIFY SCALE Name of scale used.  
 
DI_COUNSELING Participation in dietary counseling? 0=no, 1=yes. 
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COUNSEL_HR hours per week 
 
COUNSEL_SESS sessions per week 
 
DIET_TOPIC Topics covered in dietary counseling 
 
QoI Was quality of life assessed? If yes, report tool used to measure. 
 
NOTE_DIET Record any notes pertaining to dietary intervention, counseling. 
 
# FOLLOW UPS Please report the number of follow ups that took place AFTER the intervention 
period to monitor maintenance/success of participants. 
 
INTERVAL Please report the interval of follow ups, for example, 3months after intervention 
period. 
 
 
 
 
 
 
Appendix 4. Single Variant Syntax in R 
 
library ("metafor") 
 
#Pub bias for MD and CVD events 
#egger's 
regtest(model2,model="lm", data=MedDiet) 
#begg's 
ranktest(model2, data=MedDiet) 
#funnel plot 
model2trim=trimfill(model1, data=MedDiet) 
funnel(model2trim) 
 
#Pub bias for MD and IL6 
#egger's 
regtest(model4,model="lm", data=MedDiet) 
#begg's 
ranktest(model4, data=MedDiet) 
#funnel plot 
model4trim=trimfill(model4, data=MedDiet) 
funnel(model4trim) 
 
#Pub bias for MD and CRP 
#egger's 
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regtest(model6,model="lm", data=MedDiet) 
#begg's 
ranktest(model6, data=MedDiet) 
#funnel plot 
model6trim=trimfill(model6, data=MedDiet) 
funnel(model6trim) 
 
#Pub bias for MD and ICAM 
#egger's 
regtest(model8,model="lm", data=MedDiet) 
#begg's 
ranktest(model8, data=MedDiet) 
#funnel plot 
model8trim=trimfill(model8, data=MedDiet) 
funnel(model8trim) 
 
 
 
 
 
 
 
#Pub bias for MD and VCAM 
#egger's 
regtest(model10,model="lm", data=MedDiet) 
#begg's 
ranktest(model10, data=MedDiet) 
#funnel plot 
model10trim=trimfill(model10, data=MedDiet) 
funnel(model10trim) 
 
#Pub bias for MD and TG 
#egger's 
regtest(model12,model="lm", data=MedDiet) 
#begg's 
ranktest(model12, data=MedDiet) 
#funnel plot 
model10trim=trimfill(model12, data=MedDiet) 
funnel(model12trim) 
 
#Pub bias for MD and LDL 
#egger's 
regtest(model14,model="lm", data=MedDiet) 
#begg's 
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ranktest(model14, data=MedDiet) 
#funnel plot 
model12trim=trimfill(model14, data=MedDiet) 
funnel(model14trim) 
 
#Pub bias for MD and HDL 
#egger's 
regtest(model16,model="lm", data=MedDiet) 
#begg's 
ranktest(model16, data=MedDiet) 
#funnel plot 
model16trim=trimfill(model16, data=MedDiet) 
funnel(model16trim) 
 
library ("metafor") 
 
#Run model for MD and CVD events 
 
model1<-rma(d.ex.,var_d.ex.,subset=(Diet==8&Outcome==8), 
data=MedDiet,method="FE") 
model1 
model2<-rma(d.ex.,var_d.ex.,subset=(Diet==8&Outcome==8), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model2 
 
#Run model for MD and IL6 
 
model3<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==4), 
data=MedDiet,method="FE") 
model3 
model4<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==4), 
data=MedDiet,method="REML" , slab= paste(Reference, Year, sep="")) 
model4 
 
#Run model for MD and CRP 
 
model5<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==5), 
data=MedDiet,method="FE") 
model5 
model6<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==5), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model6 
 
#Run model for MD and ICAM 
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model7<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==6), 
data=MedDiet,method="FE") 
model7 
model8<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==6), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model8 
 
#Run model for MD and VCAM 
 
model9<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==7), 
data=MedDiet,method="FE") 
model9 
model10<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==7), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model10 
 
#Run model for MD and TG 
 
model11<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==1), 
data=MedDiet,method="FE") 
model11 
model12<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==1), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model12 
 
#Run model for MD and LDL 
 
model13<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==2), 
data=MedDiet,method="FE") 
model13 
model14<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==2), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model14 
 
#Run model for MD and HDL 
 
model15<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==3), 
data=MedDiet1,method="FE") 
model15 
model16<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==3), 
data=MedDiet1,method="REML", slab= paste(Reference, Year, sep="")) 
model16 
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table(MedDiet$Diet) 
 
mean(MedDiet$Weeks) 
 
#re run REML models before making forest plots 
 
model2<-rma(d.ex.,var_d.ex.,subset=(Diet==8&Outcome==8), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model2 
 
model4<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==4), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model4 
 
model6<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==5), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model6 
 
model8<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==6), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model8 
 
model10<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==7), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model10 
 
model12<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==1), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model12 
 
model14<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==2), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model14 
 
model16<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==3), 
data=MedDiet,method="REML", slab= paste(Reference, Year, sep="")) 
model16 
 
#forest plots 
#Forest plot MD and CVD events Combined 
par("usr") 
forest(model2, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, efac=2, 
col="dark blue", border="black")  
op<-par(cex=0.90, font=2, col="black")#to change the size, font, and color of the plot 
 	 103	
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color 
of the inserted text in the plot 
text (-0.10,14, "Med Diet and CVD Events") #the first number indicates where the title 
starts and the second number how high in the plot 
text(c(-4.3,4),13,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us 
the position where favors intervention starts and 7 where the position where favors 
baseline starts, and they both are at the 22 height in the plot, if you count the number of 
authors are 20, plus the line where RE Model is that is 21 rows, so the labels Author, 
and Favors are in line 22 
text(-9.8,13, "Author(s) and Year", pos=4) 
text(7.5,13, "d[95%CI]", pos=4) 
par(op) 
 
#Forest plot MD and IL6 
par("usr") 
forest(model4, xlim=c(-29,5), xlab="Standardized Mean Difference", cex=0.8, efac=2, 
col="dark blue", border="black") 
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot 
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color 
of the inserted text in the plot 
text (-10,20, "Med Diet and IL6") #the first number indicates where the title starts and 
the second number how high in the plot 
text(c(-21,0.3),19,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us 
the position where favors intervention starts and 7 where the position where favors 
baseline starts, and they both are at the 22 height in the plot, if you count the number of 
authors are 20, plus the line where RE Model is that is 21 rows, so the labels Author, 
and Favors are in line 22 
text(-28.5,19, "Author(s) and Year", pos=4) 
text(2.5,19, "d[95%CI]", pos=4) 
par(op) 
 
#Forest plot MD and CRP 
par("usr") 
forest(model6, xlim=c(-15,8), xlab="Standardized Mean Difference", cex=0.8, efac=2, 
col="dark blue", border="black") 
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot 
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color 
of the inserted text in the plot 
text (-2,29, "Med Diet and CRP") #the first number indicates where the title starts and 
the second number how high in the plot 
text(c(-7,3),28,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us the 
position where favors intervention starts and 7 where the position where favors baseline 
starts, and they both are at the 22 height in the plot, if you count the number of authors 
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are 20, plus the line where RE Model is that is 21 rows, so the labels Author, and 
Favors are in line 22 
text(-15,28, "Author(s) and Year", pos=4) 
text(8,28, "d[95%CI]", pos=4) 
par(op) 
 
#forest plot for Med Diet and ICAM 
par("usr") 
forest(model8, xlim=c(-13,5), xlab="Standardized Mean Difference", cex=0.8, efac=2, 
col="dark blue", border="black") 
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot 
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color 
of the inserted text in the plot 
text (-2.5,13, "Med Diet and ICAM") #the first number indicates where the title starts and 
the second number how high in the plot 
text(c(-6,1.5),12,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us 
the position where favors intervention starts and 7 where the position where favors 
baseline starts, and they both are at the 22 height in the plot, if you count the number of 
authors are 20, plus the line where RE Model is that is 21 rows, so the labels Author, 
and Favors are in line 22 
text(-12,12, "Author(s) and Year", pos=4) 
text(3,12, "d[95%CI]", pos=4) 
par(op) 
 
#forest plot Med Diet and VCAM 
par("usr") 
forest(model10, xlim=c(-10,9), xlab="Standardized Mean Difference", cex=0.8, efac=2, 
col="dark blue", border="black") 
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot 
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color 
of the inserted text in the plot 
text (-0.5,12, "Med Diet and VCAM") #the first number indicates where the title starts 
and the second number how high in the plot 
text(c(-4,3),11,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us the 
position where favors intervention starts and 7 where the position where favors baseline 
starts, and they both are at the 22 height in the plot, if you count the number of authors 
are 20, plus the line where RE Model is that is 21 rows, so the labels Author, and 
Favors are in line 22 
text(-9.8,11, "Author(s) and Year", pos=4) 
text(6,11, "d[95%CI]", pos=4) 
par(op) 
 
#forest plot for Med Diet and TG 
par("usr") 
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forest(model12, xlim=c(-25,10), xlab="Standardized Mean Difference", cex=0.8, efac=2, 
col="dark blue", border="black") 
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot 
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color 
of the inserted text in the plot 
text (-5,27.5, "Med Diet and TG") #the first number indicates where the title starts and 
the second number how high in the plot 
text(c(-15,3),27,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us the 
position where favors intervention starts and 7 where the position where favors baseline 
starts, and they both are at the 22 height in the plot, if you count the number of authors 
are 20, plus the line where RE Model is that is 21 rows, so the labels Author, and 
Favors are in line 22 
text(-24,27, "Author(s) and Year", pos=4) 
text(7.5,27, "d[95%CI]", pos=4) 
par(op) 
 
#forest plot for Med Diet and LDL 
par("usr") 
forest(model14, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, efac=2, 
col="dark blue", border="black") 
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot 
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color 
of the inserted text in the plot 
text (-0.5,25.4, "Med Diet and LDL") #the first number indicates where the title starts 
and the second number how high in the plot 
text(c(-4.2,3),24,c("Favors Intervention", "Favors Baseline")) #here the -8 is telling us 
the position where favors intervention starts and 7 where the position where favors 
baseline starts, and they both are at the 22 height in the plot, if you count the number of 
authors are 20, plus the line where RE Model is that is 21 rows, so the labels Author, 
and Favors are in line 22 
text(-9.20,24, "Author(s) and Year", pos=4) 
text(7,24, "d[95%CI]", pos=4) 
par(op) 
 
 
#forest plot for Med Diet and HDL 
par("usr") 
forest(model16, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8, efac=2, 
col="dark blue", border="black") 
op<-par(cex=0.70, font=2, col="black")#to change the size, font, and color of the plot 
op<-par(cex=0.80, font=2, col="dark blue") #to change the size, the font, and the color 
of the inserted text in the plot 
text (-0.5,27, "Med Diet and HDL") #the first number indicates where the title starts and 
the second number how high in the plot 
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text(c(-4,3.8),26,c("Favors Baseline", "Favors Intervention")) #here the -8 is telling us 
the position where favors intervention starts and 7 where the position where favors 
baseline starts, and they both are at the 22 height in the plot, if you count the number of 
authors are 20, plus the line where RE Model is that is 21 rows, so the labels Author, 
and Favors are in line 22 
text(-9.8,26, "Author(s) and Year", pos=4) 
text(7.5,26, "d[95%CI]", pos=4) 
par(op) 
 
 
#Regressions 
 
#Regression MD and TG 
model181<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Weeks, data= 
MedDiet, method="REML", slab= paste(Author, sep =",")) 
model181pred <- predict(model181, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet$w_d.ex. 
min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
size= 0.5 + 3.0 * (wi - min(wi))/(max(wi) - min(wi)) 
dietout1= subset(MedDiet,Diet==1 & Outcome==1) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$Weeks,dietout1$d.ex.,pch= 22, col="black", bg = "white", cex=wi, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on TG and Effect Size(d)",xlim=c(0, 208), ylim=c(-1.5, 0.5)) 
lines(seq(0,208,.1), model181pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model181pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model181pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model181) 
 
 
 
 
 
 
 
#Regression MD and LDL 
model191<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), mods=Weeks, data= 
MedDiet, method="REML", slab= paste(Author, sep =",")) 
model191pred <- predict(model191, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet$w_d.ex. 
min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
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size= 0.5 + 3.0 * (wi - min)/(max - min) 
dietout1= subset(MedDiet,Diet==1 & Outcome==2) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$Weeks,dietout1$d.ex.,pch= 22, col="black", bg = "black", cex=size, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on LDL and Effect Size(d)",xlim=c(0, 208), ylim=c(-2.0, 2.0)) 
lines(seq(0,208,.1), model191pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model191pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model191pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model191) 
 
#Regression MD and HDL 
model201<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=Weeks, data= 
MedDiet1, method="REML", slab= paste(Author, sep =",")) 
model201pred <- predict(model201, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet1$w_d.ex. 
min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
size= 0.5 + 3.0 * (wi - min)/(max - min) 
dietout1= subset(MedDiet1,Diet==1 & Outcome==3) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "black", cex=size, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on HDL and Effect Size(d)",xlim=c(0, 208), ylim=c(-1.0, 2.0)) 
lines(seq(0,208,.1), model201pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model201pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model201pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model201) 
 
#create new variable 
minweeks=8-MedDiet$Weeks 
minweeks 
 
 
 
 
 
#Regression MD and HDL minweeks 
model32<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=minweeks, 
data= MedDiet1, method="REML", slab= paste(Author, sep =",")) 
model32pred <- predict(model32, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet1$w_d.ex. 
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min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
size= 0.5 + 3.0 * (wi - min)/(max - min) 
dietout1= subset(MedDiet1,Diet==1 & Outcome==3) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "black", cex=size, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on HDL and Effect Size(d)",xlim=c(0, 208), ylim=c(-1.0, 2.0)) 
lines(seq(0,208,.1), model32pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model32pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model32pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model32) 
 
#create new variable 
maxweeks=208-MedDiet$Weeks 
maxweeks 
 
#Regression MD and HDL max weeks 
model33<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=maxweeks, 
data= MedDiet, method="REML", slab= paste(Author, sep =",")) 
model33pred <- predict(model32, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet1$w_d.ex. 
min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
size= 0.5 + 3.0 * (wi - min)/(max - min) 
dietout1= subset(MedDiet1,Diet==1 & Outcome==3) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "black", cex=size, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on HDL and Effect Size(d)",xlim=c(0, 208), ylim=c(-1.0, 2.0)) 
lines(seq(0,208,.1), model33pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model33pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model33pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model33) 
 
 
 
 
 
#Regression MD and IL6 
model211<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods=Weeks, data= 
MedDiet, method="REML", slab= paste(Author, sep =",")) 
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model211pred <- predict(model211, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet$w_d.ex. 
min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
size= 0.5 + 3.0 * (wi - min)/(max - min) 
dietout1= subset(MedDiet,Diet==1 & Outcome==4) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$Weeks,dietout1$d.ex.,pch= 22, col="black", bg = "black", cex=size, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on IL6 and Effect Size(d)",xlim=c(0, 208), ylim=c(-8.0, 0.6)) 
lines(seq(0,208,.1), model211pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model211pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model211pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model211) 
 
#Regression MD and CRP 
model221<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==5), mods=region, data= 
MedDiet, method="REML", slab= paste(Author, sep =",")) 
model221pred <- predict(model221, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet$w_d.ex. 
min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
size= 0.5 + 3.0 * (wi - min)/(max - min) 
dietout1= subset(MedDiet,Diet==1 & Outcome==5) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$region,dietout1$d.ex.,pch= 22, col="black", bg = "black", cex=size, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on CRP and Effect Size(d)",xlim=c(0, 208), ylim=c(-1.5, 0.5)) 
lines(seq(0,208,.1), model221pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model221pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model221pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model221) 
 
 
 
 
 
 
 
 
 
#Regression MD and ICAM 
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model241<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==6), mods=Weeks, data= 
MedDiet, method="REML", slab= paste(Author, sep =",")) 
model241pred <- predict(model241, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet$w_d.ex. 
min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
size= 0.5 + 3.0 * (wi - min)/(max - min) 
dietout1= subset(MedDiet,Diet==1 & Outcome==6) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$Weeks,dietout1$d.ex.,pch= 22, col="black", bg = "black", cex=size, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on ICAM and Effect Size(d)",xlim=c(0, 208), ylim=c(-10, 1)) 
lines(seq(0,208,.1), model241pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model241pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model241pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model241) 
 
#Regression MD and VCAM 
model261<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==7), mods=Weeks, data= 
MedDiet, method="REML", slab= paste(Author, sep =",")) 
model261pred <- predict(model261, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet$w_d.ex. 
min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
size= 0.5 + 3.0 * (wi - min)/(max - min) 
dietout1= subset(MedDiet,Diet==1 & Outcome==7) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "white", cex=size, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on VCAM and Effect Size(d)",xlim=c(0, 208), ylim=c(-10, 1.5)) 
lines(seq(0,208,.1), model261pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model261pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model261pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model261) 
 
#create new variable 
maxweeks=52-MedDiet$Weeks 
maxweeks 
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#Regression MD and VCAM maxweeks 
model27<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==7), mods=maxweeks, 
data= MedDiet, method="REML", slab= paste(Author, sep =",")) 
model27pred <- predict(model27, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet$w_d.ex. 
min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
size= 0.5 + 3.0 * (wi - min)/(max - min) 
dietout1= subset(MedDiet,Diet==1 & Outcome==7) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "white", cex=size, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on VCAM and Effect Size(d)",xlim=c(0, 208), ylim=c(-10, 1.5)) 
lines(seq(0,208,.1), model27pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model27pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model27pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model27) 
 
#create new variable 
minweeks=12-MedDiet$Weeks 
minweeks 
 
#Regression MD and VCAM minweeks 
model31<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==7), mods=minweeks, 
data= MedDiet, method="REML", slab= paste(Author, sep =",")) 
model31pred <- predict(model31, newmods=cbind(seq(0,208,.1))) 
wi = MedDiet$w_d.ex. 
min= min(wi, na.rm=TRUE) 
max= max(wi, na.rm=TRUE) 
size= 0.5 + 3.0 * (wi - min)/(max - min) 
dietout1= subset(MedDiet,Diet==1 & Outcome==7) #Here we have to create the 
subsample we are working on to just plot the observed values of that below 
plot(dietout1$Weeks,dietout1$d.ex.,pch= 23, col="black", bg = "white", cex=size, xlab = 
"Number of Weeks", #Plotting here the observed values of the subsample 
     ylab = "MD on VCAM and Effect Size(d)",xlim=c(0, 208), ylim=c(-10, 1.5)) 
lines(seq(0,208,.1), model31pred$pred, col = "dark blue") #Plotting here the regression 
line and confidence interval of the predictive model 
lines(seq(0,208,.1), model31pred$ci.lb, lty = "dashed", col="dark blue") 
lines(seq(0,208,.1), model31pred$ci.ub, lty = "dashed", col="dark blue") 
summary(model31) 
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Appendix 5. Multivariate Syntax in R 
 
library(metafor) 
 
#CRP 
#Calculate total number of participants (Ni) 
creactive$ni <-unlist(lapply(split(creactive,creactive$study),function(x) 
rep(sum(x$ni1)+x$ni2[1],each=nrow(x)))) 
 
#Create Variance-Covariance Matrix for Multiple Comparisons: 
calc.creactivev <- function(x) {creactivev<- matrix(1/x$ni2[1] + 
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x)) 
diag(creactivev) <- x$var 
creactivev} 
 
creactiveproV <- lapply(split(creactive,creactive$study),calc.creactivev) 
creactiveproV <-as.matrix(bdiag(creactiveproV)) 
creactiveproV 
 
##Calculating the Weighted Mean ES  
creactive$diet <-as.factor(creactive$diet) 
 
dcreactive <- rma.mv(d, var, creactiveproV, mods = ~ factor(diet) - 1,random = ~ 
diet|study,struct="UN",data = creactive,method="ML") 
dcreactive 
 
table(creactive$diet) 
 
#moderators 
#moderator Weeks 
model1<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$weeks, data = 
creactive, method="ML") 
summary (model1) 
 
#moderator females 
model2<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$fem,data = 
creactive, method="ML") 
summary (model2) 
 
#moderator proportion of females 
 	 113	
model3<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$propfem,data = 
creactive, method="ML") 
summary (model3) 
 
 
 
#moderator region 
model4<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + 
factor(creactive$region),data = creactive, method="ML") 
summary (model4) 
 
#moderator population recruit 
model5<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(pop),data = 
creactive, method="ML") 
summary (model5) 
 
#moderator age 
model6<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$age,data = 
creactive, method="ML") 
summary (model6) 
 
#moderator interlvl 
model7<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(interlvl),data = 
creactive, method="ML") 
summary (model7) 
 
#moderator mq 
model8<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$mq,data = 
creactive, method="ML") 
summary (model8) 
 
#moderator pub year 
model9<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$Year,data = 
creactive, method="ML") 
summary (model9) 
 
#moderator total n 
model10<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$ni,data = 
creactive, method="ML") 
summary (model10) 
 
#moderator score 
model11<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$score,data = 
creactive, method="ML") 
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summary (model11) 
 
#moderator number of interventions 
model12<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(numinterv),data = 
creactive, method="ML") 
summary (model12) 
 
#moderator funding source 
model13<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(fund),data = 
creactive, method="ML") 
summary (model13) 
 
#moderator ethnicity estimate 
model14<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(ethest),data = 
creactive, method="ML") 
summary (model14) 
 
#moderator proportion disease 
model16<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$diseaseprop, 
data = creactive, method="ML") 
summary (model16) 
 
#moderator number disease 
model17<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$diseasenum, 
data = creactive, method="ML") 
summary (model17) 
 
#moderator proportion meds 
model18<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$medsprop, 
data = creactive, method="ML") 
summary (model18) 
 
#moderator number meds 
model19<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$medsnum, 
data = creactive, method="ML") 
summary (model19) 
 
#moderator med type 
model20<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(medtype), data = 
creactive, method="ML") 
summary (model20) 
 
#moderator experimental setting 
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model21<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$experiset, data 
= creactive, method="ML") 
summary (model21) 
 
 
 
 
#moderator length of counseling  
model22<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$counsellength, 
data = creactive, method="ML") 
summary (model22) 
 
#moderator number of counseling sessions 
model23<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$counselnum, 
data = creactive, method="ML") 
summary (model23) 
 
#moderator language of publication 
model24<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$publang, data 
= creactive, method="ML") 
summary (model24) 
 
#moderator proportion of carb 
model25<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$carbprop, data 
= creactive, method="ML") 
summary (model25) 
 
#moderator proportion of sat fat 
model26<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$satfatprop, 
data = creactive, method="ML") 
summary (model26) 
 
#moderator proportion of total fat 
model27<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$totfatprop, 
data = creactive, method="ML") 
summary (model27) 
 
#moderator proportion of protein 
model28<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$protprop, data 
= creactive, method="ML") 
summary (model28) 
 
#moderator assessment of dietary compliance 
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model29<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + factor(dietcompl), data = 
creactive, method="ML") 
summary (model29) 
 
#moderator participation in dietary counseling 
model30<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$dietcoun, data 
= creactive, method="ML") 
summary (model30) 
#moderator proportion of cvd 
model31<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$cvd, data = 
creactive, method="ML") 
summary (model31) 
 
#moderator proportion of DM 
model32<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$dm, data = 
creactive, method="ML") 
summary (model32) 
 
#moderator proportion of MetS 
model33<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$mets, data = 
creactive, method="ML") 
summary (model33) 
 
#moderator proportion of overweight/obesity 
model34<-rma(d,var,creactiveproV, mods = ~ factor(diet) - 1 + creactive$obes, data = 
creactive, method="ML") 
summary (model34) 
 
#IL6 
 
#Calculate total number of participants (ni) 
interl$ni <-unlist(lapply(split(interl,interl$study), function(x) 
rep(sum(x$n1i)+x$n2i[1],each=nrow(x)))) 
 
#Create Variance-Covariance Matrix for Multiple Comparisons: 
calc.interv <- function(x) {interv<- matrix(1/x$n2i[1] + 
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x)) 
diag(interv) <- x$var 
interv} 
interV <- lapply(split(interl,interl$study),calc.interv) 
interV <-as.matrix(bdiag(interV)) 
interV 
 
##Calculating the Weighted Mean ES  
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interl$diet <-as.factor(interl$diet) 
 
dinterl <- rma.mv(d, var, interV, mods = ~ factor(diet) - 1,random = ~ 
diet|study,struct="UN",data = interl,method="ML") 
dinterl 
 
table(interl$diet) 
 
#moderators 
#moderator Weeks 
model35<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$weeks,data = interl, 
method="ML") 
summary (model35) 
 
#moderator females 
model36<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$fem,data = interl, 
method="ML") 
summary (model36) 
 
#moderator region 
model37<-rma(d,var,interV, mods = ~ factor(diet) - 1 + ~ factor(region),data = interl, 
method="ML") 
summary (model37) 
 
#moderator population recruit 
model38<-rma(d,var,interV, mods = ~ factor(diet) - 1 + ~ factor(pop),data = interl, 
method="ML") 
summary (model38) 
 
#moderator age 
model39<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$age,data = interl, 
method="ML") 
summary (model39) 
 
#moderator interlvl 
model40<-rma(d,var,interV, mods = ~ factor(diet) - 1 + ~ factor(interlvl),data = interl, 
method="ML") 
summary (model40) 
 
#moderator mq 
model41<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$mq,data = interl, 
method="ML") 
summary (model41) 
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#moderator pub year 
model42<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$Year,data = interl, 
method="ML") 
summary (model42) 
 
#moderator total n 
model43<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$ni,data = interl, 
method="ML") 
summary (model43) 
 
#moderator score 
model44<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$score,data = interl, 
method="ML") 
summary (model44) 
 
#moderator funding source 
model45<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$fund,data = interl, 
method="ML") 
summary (model45) 
 
#moderator number of interventions 
model45<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$numinterv,data = interl, 
method="ML") 
summary (model45) 
 
#moderator ethnicity estimate 
model46<-rma(d,var,interV, mods = ~ factor(diet) - 1 + factor(ethest),data = interl, 
method="ML") 
summary (model46) 
 
#moderator proportion disease 
model48<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$diseaseprop, data = interl, 
method="ML") 
summary (model48) 
 
#moderator number disease 
model49<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$diseasenum, data = interl, 
method="ML") 
summary (model49) 
 
#moderator proportion meds 
model50<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$medsprop, data = interl, 
method="ML") 
summary (model50) 
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#moderator number meds 
model51<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$medsnum, data = interl, 
method="ML") 
summary (model51) 
 
#moderator med type 
model52<-rma(d,var,interV, mods = ~ factor(diet) - 1 + factor(medtype), data = interl, 
method="ML") 
summary (model52) 
 
#moderator experimental setting 
model53<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$experiset, data = interl, 
method="ML") 
summary (model53) 
#moderator length of counseling  
model54<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$counsellength, data = 
interl, method="ML") 
summary (model54) 
 
#moderator number of counseling sessions 
model55<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$counselnum, data = interl, 
method="ML") 
summary (model55) 
 
#moderator language of publication 
model56<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$publang, data = interl, 
method="ML") 
summary (model56) 
 
#moderator proportion of carb 
model57<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$carbprop, data = interl, 
method="ML") 
summary (model57) 
 
#moderator proportion of sat fat 
model58<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$satfatprop, data = interl, 
method="ML") 
summary (model58) 
 
#moderator proportion of total fat 
model59<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$totfatprop, data = interl, 
method="ML") 
summary (model59) 
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#moderator proportion of protein 
model60<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$protprop, data = interl, 
method="ML") 
summary (model60) 
 
#moderator assessment of dietary compliance 
model61<-rma(d,var,interV, mods = ~ factor(diet) - 1 + factor(dietcompl), data =interl, 
method="ML") 
summary (model61) 
 
#moderator participation in dietary counseling 
model62<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$dietcoun, data = interl, 
method="ML") 
summary (model62) 
 
#moderator proportion of cvd 
model63<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$cvd, data = interl, 
method="ML") 
summary (model63) 
 
#moderator proportion of DM 
model64<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$dm, data = interl, 
method="ML") 
summary (model64) 
 
#moderator proportion of MetS 
model65<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$mets, data = interl, 
method="ML") 
summary (model65) 
 
#moderator proportion of overweight/obesity 
model66<-rma(d,var,interV, mods = ~ factor(diet) - 1 + interl$obes, data = interl, 
method="ML") 
summary (model66) 
 
#ICAM 
 
#Calculate total number of participants (Ni) 
ICAMdata$ni <-unlist(lapply(split(ICAMdata,ICAMdata$study),function(x) 
rep(sum(x$n1i)+x$n2i[1],each=nrow(x)))) 
 
#Create Variance-Covariance Matrix for Multiple Comparisons: 
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calc.icamv <- function(x) {icamv<- matrix(1/x$n2i[1] + 
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x)) 
diag(icamv) <- x$var 
icamv} 
icamV <- lapply(split(ICAMdata, ICAMdata$study),calc.icamv) 
icamV <-as.matrix(bdiag(icamV)) 
icamV 
 
##Calculating the Weighted Mean ES  
ICAMdata$diet <-as.factor(ICAMdata$diet) 
 
dicam <- rma.mv(d, var, icamV, mods = ~ factor(diet) - 1,random = ~ 
diet|study,struct="UN",data = ICAMdata,method="ML") 
dicam 
 
table(ICAMdata$diet) 
 
 
 
#moderators 
#moderator Weeks 
model67<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$weeks,data = 
ICAMdata, method="ML") 
summary (model67) 
 
#moderator females 
model68<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$fem,data = 
ICAMdata, method="ML") 
summary (model68) 
 
#moderator region 
model69<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ~ factor(ICAMdata$region),data 
= ICAMdata, method="ML") 
summary (model69) 
 
#moderator population recruit 
model70<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$pop,data = 
ICAMdata, method="ML") 
summary (model70) 
 
#moderator age 
model71<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$age,data = 
ICAMdata, method="ML") 
summary (model71) 
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#moderator interlvl 
model72<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ~ factor(interlvl),data = 
ICAMdata, method="ML") 
summary (model72) 
 
#moderator mq 
model73<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$mq,data = ICAMdata, 
method="ML") 
summary (model73) 
 
#moderator pub year 
model74<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$Year,data = 
ICAMdata, method="ML") 
summary (model74) 
 
 
 
 
#moderator total n 
model75<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$ni,data = ICAMdata, 
method="ML") 
summary (model75) 
 
#moderator score 
model76<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$score,data = 
ICAMdata, method="ML") 
summary (model76) 
 
#moderator funding source 
model77<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + factor(fund),data = ICAMdata, 
method="ML") 
summary (model77) 
 
#moderator number of interventions 
model78<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + factor(numinterv),data = 
ICAMdata, method="ML") 
summary (model78) 
 
#moderator ethnicity estimate 
model80<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + factor(ethest),data = ICAMdata, 
method="ML") 
summary (model80) 
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#moderator proportion disease 
model81<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$diseaseprop, data = 
ICAMdata, method="ML") 
summary (model81) 
 
#moderator number disease 
model82<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$diseasenum, data = 
ICAMdata, method="ML") 
summary (model82) 
 
#moderator proportion meds 
model83<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdatal$medsprop, data = 
ICAMdata, method="ML") 
summary (model83) 
 
#moderator number meds 
model84<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$medsnum, data = 
ICAMdata, method="ML") 
summary (model84) 
#moderator med type 
model85<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + factor(medtype), data = 
ICAMdata, method="ML") 
summary (model85) 
 
#moderator experimental setting 
model86<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$experiset, data = 
ICAMdata, method="ML") 
summary (model86) 
 
#moderator length of counseling  
model87<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$counsellength, data = 
ICAMdata, method="ML") 
summary (model87) 
 
#moderator number of counseling sessions 
model88<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$counselnum, data = 
ICAMdata, method="ML") 
summary (model88) 
 
#moderator language of publication 
model89<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$publang, data = 
ICAMdata, method="ML") 
summary (model89) 
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#moderator proportion of carb 
model90<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$carbprop, data = 
ICAMdata, method="ML") 
summary (model90) 
 
#moderator proportion of sat fat 
model91<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$satfatprop, data = 
ICAMdata, method="ML") 
summary (model91) 
 
#moderator proportion of total fat 
model92<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$totfatprop, data = 
ICAMdata, method="ML") 
summary (model92) 
 
#moderator proportion of protein 
model93<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + i ICAMdata$protprop, data = 
ICAMdata, method="ML") 
summary (model93) 
 
#moderator assessment of dietary compliance 
model94<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + factor(dietcompl), data 
=ICAMdata, method="ML") 
summary (model94) 
 
#moderator participation in dietary counseling 
model95<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$dietcoun, data = 
ICAMdata, method="ML") 
summary (model95) 
 
#moderator proportion of cvd 
model96<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$cvd, data = 
ICAMdata, method="ML") 
summary (model96) 
 
#moderator proportion of DM 
model97<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$dm, data = 
ICAMdata, method="ML") 
summary (model97) 
 
#moderator proportion of MetS 
model98<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$mets, data = 
ICAMdata, method="ML") 
summary (model98) 
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#moderator proportion of overweight/obesity 
model99<-rma(d,var,icamV, mods = ~ factor(diet) - 1 + ICAMdata$obes, data = 
ICAMdata, method="ML") 
summary (model99) 
 
 
#VCAM 
 
#Calculate total number of participants (Ni) 
VCAMdata$ni <-unlist(lapply(split(VCAMdata,VCAMdata$study),function(x) 
rep(sum(x$n1i)+x$n2i[1],each=nrow(x)))) 
 
#Create Variance-Covariance Matrix for Multiple Comparisons: 
calc.vcamv <- function(x) {vcamv<- matrix(1/x$n2i[1] + 
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x)) 
diag(vcamv) <- x$var 
vcamv} 
vcamV <- lapply(split(VCAMdata,VCAMdata$study),calc.vcamv) 
vcamV <-as.matrix(bdiag(vcamV)) 
vcamV 
 
##Calculating the Weighted Mean ES  
VCAMdata$diet <-as.factor(VCAMdata$diet) 
 
dvcam <- rma.mv(d, var, vcamV, mods = ~ factor(diet) - 1,random = ~ 
diet|study,struct="UN",data = VCAMdata,method="ML") 
dvcam 
 
table(VCAMdata$diet) 
 
#moderators 
#moderator Weeks 
model100<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$weeks,data = 
VCAMdata, method="ML") 
summary (model100) 
 
#moderator females 
model101<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$fem,data = 
VCAMdata, method="ML") 
summary (model101) 
 
#moderator region 
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model102<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$region,data = 
VCAMdata, method="ML") 
summary (model102) 
 
#moderator population recruit 
model103<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$pop,data = 
VCAMdata, method="ML") 
summary (model103) 
 
#moderator age 
model104<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$age,data = 
VCAMdata, method="ML") 
summary (model104) 
 
#moderator interlvl 
model105<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + ~ factor(interlvl),data = 
VCAMdata, method="ML") 
summary (model105) 
 
 
#moderator mq 
model106<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$mq,data = 
VCAMdata, method="ML") 
summary (model106) 
 
#moderator pub year 
model107<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$Year,data = 
VCAMdata, method="ML") 
summary (model107) 
 
#moderator total n 
model108<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$ni,data = 
VCAMdata, method="ML") 
summary (model108) 
 
#moderator score 
model109<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$score,data = 
VCAMdata, method="ML") 
summary (model109) 
 
#moderator funding source 
model110<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + factor(fund),data = VCAMdata, 
method="ML") 
summary (model110) 
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#moderator number of interventions 
model111<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + factor(numinterv),data = 
VCAMdata, method="ML") 
summary (model111) 
 
#moderator ethnicity estimate 
model112<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + factor(ethest),data = 
VCAMdata, method="ML") 
summary (model112) 
 
#moderator proportion disease 
model113<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$diseaseprop, data 
= VCAMdata, method="ML") 
summary (model113) 
 
#moderator number disease 
model114<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$diseasenum, data 
= VCAMdata, method="ML") 
summary (model114) 
#moderator proportion meds 
model115<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdatal$medsprop, data = 
VCAMdata, method="ML") 
summary (model115) 
 
#moderator number meds 
model116<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$medsnum, data = 
VCAMdata, method="ML") 
summary (model116) 
 
#moderator med type 
model117<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + factor(medtype), data = 
VCAMdata, method="ML") 
summary (model117) 
 
#moderator experimental setting 
model118<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$experiset, data = 
VCAMdata, method="ML") 
summary (model118) 
 
#moderator length of counseling  
model119<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$counsellength, 
data = VCAMdata, method="ML") 
summary (model119) 
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#moderator number of counseling sessions 
model120<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$counselnum, data 
= VCAMdata, method="ML") 
summary (model120) 
 
#moderator language of publication 
model121<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$publang, data = 
VCAMdata, method="ML") 
summary (model121) 
 
#moderator proportion of carb 
model122<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$carbprop, data = 
VCAMdata, method="ML") 
summary (model122) 
 
#moderator proportion of sat fat 
model123<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$satfatprop, data = 
VCAMdata, method="ML") 
summary (model123) 
#moderator proportion of total fat 
model124<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$totfatprop, data = 
VCAMdata, method="ML") 
summary (model124) 
 
#moderator proportion of protein 
model125<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$protprop, data = 
VCAMdata, method="ML") 
summary (model125) 
 
#moderator assessment of dietary compliance 
model126<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + factor(dietcompl), data 
=VCAMdata, method="ML") 
summary (model126) 
 
#moderator participation in dietary counseling 
model127<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$dietcoun, data = 
VCAMdata, method="ML") 
summary (model127) 
 
#moderator proportion of cvd 
model128<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$cvd, data = 
VCAMdata, method="ML") 
summary (model128) 
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#moderator proportion of DM 
model129<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$dm, data = 
VCAMdata, method="ML") 
summary (model129) 
 
#moderator proportion of MetS 
model130<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$mets, data = 
VCAMdata, method="ML") 
summary (model130) 
 
#moderator proportion of overweight/obesity 
model131<-rma(d,var,vcamV, mods = ~ factor(diet) - 1 + VCAMdata$obes, data = 
VCAMdata, method="ML") 
summary (model131) 
 
 
 
 
 
#TG 
 
#Calculate total number of participants (Ni) 
tg$ni <-unlist(lapply(split(tg,tg$study),function(x) 
rep(sum(x$n1i)+x$n2i[1],each=nrow(x)))) 
 
#Create Variance-Covariance Matrix for Multiple Comparisons: 
calc.tgv <- function(x) {tgv<- matrix(1/x$n2i[1] + 
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x)) 
diag(tgv) <- x$var 
tgv} 
 
tgV <- lapply(split(tg,tg$study),calc.tgv) 
tgV <-as.matrix(bdiag(tgV)) 
tgV 
 
 
##Calculating the Weighted Mean ES  
tg$diet <-as.factor(tg$diet) 
 
dtg <- rma.mv(d, var, tgV, mods = ~ factor(diet) - 1,random = ~ 
diet|study,struct="UN",data = tg,method="ML") 
dtg 
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table(tg$diet) 
 
#moderators 
#moderator Weeks 
model132<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$weeks, data = tg, 
method="ML") 
summary (model132) 
 
#moderator females 
model133<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$fem,data = tg, method="ML") 
summary (model133) 
 
#moderator region 
model134<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(tg$region),data = tg, 
method="ML") 
summary (model134) 
 
#moderator population recruit 
model135<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(pop),data = tg, 
method="ML") 
summary (model135) 
 
 
#moderator age 
model136<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$age,data = tg, method="ML") 
summary (model136) 
 
#moderator interlvl 
model137<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(interlvl),data = tg, 
method="ML") 
summary (model137) 
 
#moderator mq 
model138<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$mq,data = tg, method="ML") 
summary (model138) 
 
#moderator pub year 
model139<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$Year,data = tg, method="ML") 
summary (model139) 
 
#moderator total n 
model140<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$ni,data = tg, method="ML") 
summary (model140) 
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#moderator score 
model141<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$score,data = tg, method="ML") 
summary (model141) 
 
#moderator funding  
model142<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(fund),data = tg, 
method="ML") 
summary (model142) 
 
#moderator number of interventions 
model143<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(numinterv),data = tg, 
method="ML") 
summary (model143) 
 
#moderator ethnicity estimate 
model144<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(ethest),data = tg, 
method="ML") 
summary (model144) 
 
#moderator proportion disease 
model145<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$diseaseprop, data = tg, 
method="ML") 
summary (model145) 
 
#moderator number disease 
model146<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$diseasenum, data = tg, 
method="ML") 
summary (model146) 
 
#moderator proportion meds 
model147<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$medsprop, data = tg, 
method="ML") 
summary (model147) 
 
#moderator number meds 
model148<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$medsnum, data = tg, 
method="ML") 
summary (model148) 
 
#moderator med type 
model149<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(medtype), data = tg, 
method="ML") 
summary (model149) 
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#moderator experimental setting 
model150<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$experiset, data =tg, 
method="ML") 
summary (model150) 
 
#moderator length of counseling  
model151<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$counsellength, data = tg, 
method="ML") 
summary (model151) 
 
#moderator number of counseling sessions 
model152<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$counselnum, data = tg, 
method="ML") 
summary (model152) 
 
#moderator language of publication 
model153<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$publang, data = tg, 
method="ML") 
summary (model153) 
 
#moderator proportion of carb 
model154<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$carbprop, data = tg, 
method="ML") 
summary (model154) 
 
#moderator proportion of sat fat 
model155<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$satfatprop, data = tg, 
method="ML") 
summary (model155) 
 
#moderator proportion of total fat 
model156<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$totfatprop, data = tg, 
method="ML") 
summary (model156) 
 
 
 
#moderator proportion of protein 
model157<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$protprop, data = tg, 
method="ML") 
summary (model157) 
 
#moderator assessment of dietary compliance 
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model158<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + factor(dietcompl), data =tg, 
method="ML") 
summary (model158) 
 
#moderator participation in dietary counseling 
model159<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$dietcoun, data = tg, 
method="ML") 
summary (model159) 
 
#moderator proportion of cvd 
model160<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$cvd, data = tg, method="ML") 
summary (model160) 
 
#moderator proportion of DM 
model161<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$dm, data = tg, method="ML") 
summary (model161) 
 
#moderator proportion of MetS 
model162<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$mets, data = tg, method="ML") 
summary (model162) 
 
#moderator proportion of overweight/obesity 
model163<-rma(d,var,tgV, mods = ~ factor(diet) - 1 + tg$obes, data = tg, method="ML") 
summary (model163) 
 
 
#LDL 
 
#Calculate total number of participants (Ni) 
LDLdata$ni <-unlist(lapply(split(LDLdata,LDLdata$study),function(x) 
rep(sum(x$n1i)+x$n2i[1],each=nrow(x)))) 
 
#Create Variance-Covariance Matrix for Multiple Comparisons: 
calc.ldlv <- function(x) {ldlv<- matrix(1/x$n2i[1] + 
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x)) 
diag(ldlv) <- x$var 
ldlv} 
 
ldlV <- lapply(split(LDLdata,LDLdata$study),calc.ldlv) 
ldlV <-as.matrix(bdiag(ldlV)) 
ldlV 
 
##Calculating the Weighted Mean ES  
LDLdata$diet <-as.factor(LDLdata$diet) 
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dldl <- rma.mv(d, var, ldlV, mods = ~ factor(diet) - 1,random = ~ 
diet|study,struct="UN",data = LDLdata,method="ML") 
dldl 
 
table(LDLdata$diet) 
 
#moderators 
#moderator Weeks 
model164<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + LDLdata$weeks, data = ldl, 
method="ML") 
summary (model164) 
 
#moderator females 
model165<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + LDLdata$fem,data = ldl, 
method="ML") 
summary (model165) 
 
#moderator region 
model166<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ~ factor(LDLdata$region),data = 
ldl, method="ML") 
summary (model166) 
 
#moderator population recruit 
model167<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(ldl$pop),data = ldl, 
method="ML") 
summary (model167) 
 
#moderator age 
model168<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$age,data = ldl, method="ML") 
summary (model168) 
 
#moderator interlvl 
model169<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(ldl$interlvl),data = ldl, 
method="ML") 
summary (model169) 
 
#moderator mq 
model170<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$mq,data = ldl, method="ML") 
summary (model170) 
 
 
#moderator pub year 
model171<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$Year,data = ldl, method="ML") 
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summary (model171) 
 
#moderator total n 
model172<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$ni,data = ldl, method="ML") 
summary (model172) 
 
#moderator score 
model173<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$score,data = ldl, 
method="ML") 
summary (model173) 
 
#moderator fund 
model174<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(fund),data = ldl, 
method="ML") 
summary (model174) 
 
#moderator number interventions 
model175<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(numinterv),data = ldl, 
method="ML") 
summary (model175) 
 
#moderator ethnicity estimate 
model176<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(ethest),data = ldl, 
method="ML") 
summary (model176) 
 
#moderator proportion disease 
model177<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$diseaseprop, data = ldl, 
method="ML") 
summary (model177) 
 
#moderator number disease 
model178<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$diseasenum, data = ldl, 
method="ML") 
summary (model178) 
 
#moderator proportion meds 
model179<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$medsprop, data = ldl, 
method="ML") 
summary (model179) 
 
#moderator number meds 
model180<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$medsnum, data = ldl, 
method="ML") 
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summary (model180) 
 
 
#moderator med type 
model181<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + factor(medtype), data = ldl, 
method="ML") 
summary (model181) 
 
#moderator experimental setting 
model182<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$experiset, data = ldl, 
method="ML") 
summary (model182) 
 
#moderator length of counseling  
model183<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$counsellength, data = ldl, 
method="ML") 
summary (model183) 
 
#moderator number of counseling sessions 
model184<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$counselnum, data = ldl, 
method="ML") 
summary (model184) 
 
#moderator language of publication 
model185<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$publang, data = ldl, 
method="ML") 
summary (model185) 
 
#moderator proportion of carb 
model186<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$carbprop, data = ldl, 
method="ML") 
summary (model186) 
 
#moderator proportion of sat fat 
model187<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$satfatprop, data = ldl, 
method="ML") 
summary (model187) 
 
#moderator proportion of total fat 
model188<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$totfatprop, data = ldl, 
method="ML") 
summary (model188) 
 
#moderator proportion of protein 
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model189<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + ldl$protprop, data = ldl, 
method="ML") 
summary (model189) 
 
#moderator assessment of dietary compliance 
model190<-rma(d,var, ldlV, mods = ~ factor(diet) - 1 + factor(dietcompl), data = ldl, 
method="ML") 
summary (model190) 
 
#moderator participation in dietary counseling 
model191<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$dietcoun, data = ldl, 
method="ML") 
summary (model191) 
 
#moderator proportion of cvd 
model192<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$cvd, data = ldl, method="ML") 
summary (model192) 
 
#moderator proportion of DM 
model193<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$dm, data = ldl, method="ML") 
summary (model193) 
 
#moderator proportion of MetS 
model194<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$mets, data = ldl, 
method="ML") 
summary (model194) 
 
#moderator proportion of overweight/obesity 
model195<-rma(d,var,ldlV, mods = ~ factor(diet) - 1 + ldl$obes, data = ldl, 
method="ML") 
summary (model195) 
 
 
#HDL 
 
#Calculate total number of participants (Ni) 
hdl$ni <-unlist(lapply(split(hdl,hdl$study),function(x) 
rep(sum(x$n1i)+x$n2i[1],each=nrow(x)))) 
 
#Create Variance-Covariance Matrix for Multiple Comparisons: 
calc.hdlv <- function(x) {hdlv<- matrix(1/x$n2i[1] + 
outer(x$d,x$d,"*")/(2*x$ni[1]),nrow=nrow(x),ncol=nrow(x)) 
diag(hdlv) <- x$var 
hdlv} 
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hdlV <- lapply(split(hdl,hdl$study),calc.hdlv) 
hdlV <-as.matrix(bdiag(hdlV)) 
hdlV 
 
##Calculating the Weighted Mean ES  
hdl$diet <-as.factor(hdl$diet) 
 
dhdl <- rma.mv(d, var, hdlV, mods = ~ factor(diet) - 1,random = ~ 
diet|study,struct="UN",data = hdl,method="ML") 
dhdl 
 
table(hdl$diet) 
 
#moderators 
#moderator Weeks 
model196<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$weeks, data = hdl, 
method="ML") 
summary (model196) 
 
#moderator females 
model197<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$fem,data = hdl, 
method="ML") 
summary (model197) 
 
#moderator region 
model198<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(hdl$region),data = hdl, 
method="ML") 
summary (model198) 
 
#moderator population recruit 
model199<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(pop),data = hdl, 
method="ML") 
summary (model199) 
 
#moderator age 
model200<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$age,data = hdl, 
method="ML") 
summary (model201) 
 
#moderator interlvl 
model202<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(interlvl),data = hdl, 
method="ML") 
summary (model202) 
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#moderator mq 
model203<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$mq,data = hdl, 
method="ML") 
summary (model203) 
 
#moderator pub year 
model204<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$Year,data = hdl, 
method="ML") 
summary (model204) 
 
#moderator total population 
model205<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$ni,data = hdl, method="ML") 
summary (model205) 
 
#moderator score 
model206<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$score,data = hdl, 
method="ML") 
summary (model206) 
 
 
#moderator funding source 
model207<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(fund),data = hdl, 
method="ML") 
summary (model207) 
 
#moderator number of interventions 
model208<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(numinterv),data = hdl, 
method="ML") 
summary (model208) 
 
#moderator ethnicity estimate 
model209<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(ethest),data = hdl, 
method="ML") 
summary (model209) 
 
#moderator proportion disease 
model210<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$diseaseprop, data = hdl, 
method="ML") 
summary (model210) 
 
#moderator number disease 
model211<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$diseasenum, data = hdl, 
method="ML") 
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summary (model211) 
 
#moderator proportion meds 
model212<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$medsprop, data = hdl, 
method="ML") 
summary (model212) 
 
#moderator number meds 
model213<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$medsnum, data = hdl, 
method="ML") 
summary (model213) 
 
#moderator med type 
model214<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + factor(medtype), data = hdl, 
method="ML") 
summary (model214) 
 
#moderator experimental setting 
model215<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$experiset, data = hdl, 
method="ML") 
summary (model215) 
 
 
#moderator length of counseling  
model216<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$counsellength, data = hdl, 
method="ML") 
summary (model216) 
 
#moderator number of counseling sessions 
model217<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$counselnum, data = hdl, 
method="ML") 
summary (model217) 
 
#moderator language of publication 
model218<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$publang, data = hdl, 
method="ML") 
summary (model218) 
 
#moderator proportion of carb 
model219<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$carbprop, data = hdl, 
method="ML") 
summary (model219) 
 
#moderator proportion of sat fat 
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model220<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$satfatprop, data = hdl, 
method="ML") 
summary (model220) 
 
#moderator proportion of total fat 
model221<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$totfatprop, data = hdl, 
method="ML") 
summary (model221) 
 
#moderator proportion of protein 
model222<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + hdl$protprop, data = hdl, 
method="ML") 
summary (model222) 
 
#moderator assessment of dietary compliance 
model223<-rma(d,var, hdlV, mods = ~ factor(diet) - 1 + factor(dietcompl), data = hdl, 
method="ML") 
summary (model223) 
 
#moderator participation in dietary counseling 
model224<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$dietcoun, data = hdl, 
method="ML") 
summary (model224) 
 
#moderator proportion of cvd 
model225<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$cvd, data = hdl, 
method="ML") 
summary (model225) 
 
#moderator proportion of DM 
model226<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$dm, data = hdl, 
method="ML") 
summary (model226) 
 
#moderator proportion of MetS 
model227<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$mets, data = hdl, 
method="ML") 
summary (model227) 
 
#moderator proportion of overweight/obesity 
model228<-rma(d,var,hdlV, mods = ~ factor(diet) - 1 + hdl$obes, data = hdl, 
method="ML") 
summary (model228) 
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